Sharekhan

Aurobindo Pharma Ltd

Thu 13/03/2025,15:59:23 | NSE : AUROPHARMA

₹ 1094.75-13.15 (-1.19%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1109.00

Previous Close

₹ 1107.90

Volume

516686

Mkt Cap ( Rs. Cr)

₹63583.26

High

₹ 1117.10

Low

₹ 1090.00

52 Week High

₹ 1592.00

52 Week Low

₹ 984.30

Book Value Per Share

₹ 531.65

Dividend Yield

0.41

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Aurobindo Pharma Ltd

Your Vote -

Buy

71.46%

Hold

20.49%

Sell

8.05%

71.46%

14098 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

1094.75

765

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

765

Option Chain

Analyzes market sentiment, predicts Aurobindo Pharma Ltd' movement.

Call Price Open interest Strike Price Put Price Open interest

News

Media spotlight triggers stock stock attention, sentiment.

  • Aurobindo Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    12 Mar 2025, 3:57PM Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
  • Aurobindo Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    11 Mar 2025, 5:55PM Aurobindo Pharma Limited has informed the Exchange about Schedule of meet and Presentation
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    11 Mar 2025, 5:51PM Intimation of Investor conference arranged by Antique Stock Broking to be held on March 19, 2025
  • Aurobindo Pharma - General Updates

    5 Mar 2025, 9:54AM Aurobindo Pharma Limited has informed the Exchange about General Updates
  • Auro Vaccines terminates license agreement for early-stage pediatric vaccine

    5 Mar 2025, 9:57AM Aurobindo Pharma said that its wholly owned step down subsidiary Auro Vaccines has terminated its License Agreement with Hilleman Laboratories Singap
  • Aurobindo Pharma - Termination Of License Agreement With Hilleman Laboratories Singapore Pte, Limited By Auro Vaccines Privat

    5 Mar 2025, 9:50AM Intimation of termination of License Agreement with Hilleman Laboratories Singapore Pte. Limited by Auro Vaccines Private Limited, a wholly owned step
  • Aurobindo Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Mar 2025, 5:26PM Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Mar 2025, 5:17PM Intimation of investor meet scheduled on March 12, 2025.
  • Aurobindo Pharma - Action(s) initiated or orders passed

    1 Mar 2025, 3:31PM Aurobindo Pharma Limited has informed the Exchange about Action(s) initiated or orders passed
  • Aurobindo Pharma - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    1 Mar 2025, 3:27PM Intimation of order received from o/o Deputy Commissioner (ST) (FAC), STU-1, Punjaagutta, Hyderabad.
  • Aurobindo Pharma - Acquisition

    28 Feb 2025, 5:55PM Aurobindo Pharma Limited has informed the Exchange about Acquisition
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Updates on Acquisition

    28 Feb 2025, 5:48PM Intimation of completion of purchase of entire 80% Equity share capital of Tergene Biotech Limited, Stepdown subsidiary of the Company held by by Aur
  • Aurobindo Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Feb 2025, 12:21PM Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
  • Aurobindo Pharma - Updates

    20 Feb 2025, 7:56AM Aurobindo Pharma Limited has informed the Exchange regarding 'Classification of US FDA Inspection at one of the warehouses of Aurobindo Pharma USA Inc
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 Feb 2025, 12:19PM Intimation of Investor Group Plant visit arranged by B&K Securities
  • Aurobindo Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    19 Feb 2025, 12:49PM Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    19 Feb 2025, 12:47PM Intimation of Investor Meet on February 25, 2025
  • Aurobindo Pharma - Updates

    18 Feb 2025, 6:44PM Aurobindo Pharma Limited has informed the Exchange regarding 'Completion of US FDA Pre-Approval Inspection (PAI) at Eugia Steriles Private Limited, a
  • Aurobindo Pharma - Completion Of US FDA Pre-Approval Inspection (PAI) At Eugia Steriles Private Limited, A 100% Stepdown Subs

    18 Feb 2025, 6:41PM Intimation of completion of USFDA pre-approval (PAI) of Eugia Steriles Private Limited, a 100% stepdown subsidiary of the Company.
  • Aurobindo Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    18 Feb 2025, 12:00PM Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    18 Feb 2025, 11:57AM Intimation of Plant Visit by investor Group at Jadcherla Plant on February 21, 2025
  • Aurobindo Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Feb 2025, 6:10PM Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    17 Feb 2025, 6:08PM Intimation of Plant Visit by Investor Group on February 28, 2025.
  • Aurobindo Pharma - Copy of Newspaper Publication

    14 Feb 2025, 12:52PM Aurobindo Pharma Limited has informed the Exchange about Copy of Newspaper Publication
  • Aurobindo Pharma - General Updates

    13 Feb 2025, 6:36PM Aurobindo Pharma Limited has informed the Exchange about General Updates
  • Aurobindo Pharma - Curateq Biologics Received Marketing Authorisation For Zefyltir, A Filgrastim Biosimilar

    13 Feb 2025, 6:34PM Intimation of receipt of marketing authorisation for Zefylti from the European Commission.
  • Aurobindo Pharma - Notice Of Shareholders Meetings-XBRL

    13 Feb 2025, 3:52PM AUROBINDO PHARMA LIMITED has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot
  • Aurobindo Pharma - Shareholders meeting

    13 Feb 2025, 3:03PM Aurobindo Pharma Limited has informed the Exchange regarding Notice of Postal Ballot
  • Aurobindo Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Feb 2025, 12:08PM Aurobindo Pharma Limited has informed the Exchange about Transcript
  • Aurobindo Pharma - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    13 Feb 2025, 3:08PM Submission of Notice of Postal Ballot
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    13 Feb 2025, 12:05PM Submission of Q3 of FY2025 earnings call transcript
  • Aurobindo Pharma - Copy of Newspaper Publication

    8 Feb 2025, 3:01PM Aurobindo Pharma Limited has informed the Exchange about Copy of Newspaper Publication
  • Aurobindo Pharma - Acquisition-XBRL

    7 Feb 2025, 2:48PM AUROBINDO PHARMA LIMITED has informed the Exchange regarding Acquisition
  • Aurobindo Pharma - Acquisition-XBRL

    7 Feb 2025, 2:46PM AUROBINDO PHARMA LIMITED has informed the Exchange regarding Acquisition
  • Aurobindo Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    7 Feb 2025, 2:42PM AUROBINDO PHARMA LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Ag
  • Aurobindo Pharma - General Updates

    7 Feb 2025, 11:49AM Aurobindo Pharma Limited has informed the Exchange about General Updates
  • Aurobindo Pharma - Integrated Filing- Financial

    7 Feb 2025, 10:52AM Submission of Integrated filing (Financials) for the quarter ended December 31, 2024
  • Aurobindo Pharma - Integrated Filing (Financial)

    7 Feb 2025, 10:47AM Submission of Integrated Filing (Financials) for the quarter ended December 31, 2024.
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Change in Directorate

    6 Feb 2025, 8:38PM Intimation of Re-appointment of Mr.Santanu Mukherjee as Non-executive Independent Director for the second term.
  • Aurobindo Pharma - Appointment

    6 Feb 2025, 8:35PM Aurobindo Pharma Limited has informed the Exchange regarding Appointment of Mr Santanu Muk as Non- Executive Independent Director of the company w.e.f
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Acquisition

    6 Feb 2025, 8:29PM Intimation of acquisition of 26% stake in Swarnaaskshu Solar Power Private Limited
  • Aurobindo Pharma - Acquisition

    6 Feb 2025, 8:26PM Aurobindo Pharma Limited has informed the Exchange about Acquisition
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

    6 Feb 2025, 8:23PM Submission of Investor Presentation
  • Aurobindo Pharma - Investor Presentation

    6 Feb 2025, 8:19PM Aurobindo Pharma Limited has informed the Exchange about Investor Presentation
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    6 Feb 2025, 8:16PM Press release on Unaudited Financial Results for the third quarter and nine months period ended 31.12.2024
  • Aurobindo Pharma - Press Release

    6 Feb 2025, 8:13PM Aurobindo Pharma Limited has informed the Exchange regarding a press release dated February 06, 2025, titled ""Press Release on Unaudited Financial Re
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Acquisition

    6 Feb 2025, 8:10PM Intimation of entire 80% of the equity share capital of Tergene Biotech Private Limited by the Company from the Auro Vaccines Private Limited
  • Aurobindo Pharma - Acquisition

    6 Feb 2025, 8:03PM Aurobindo Pharma Limited has informed the Exchange about Acquisition
  • Aurobindo Pharma - Unaudited Financial Results For The Quarter And Nine Months Period Ended December 31, 2024

    6 Feb 2025, 7:57PM submission of Unaudited financial results for the quarter and nine months period ended December 31, 2024
  • Aurobindo Pharma Q3 net profit down 24.32% at Rs 472.05 cr

    6 Feb 2025, 7:51PM The company reported standalone net profit of Rs 472.05 crore for the quarter ended December 31, 2024 as compared to Rs 623.78 crore in the same perio
  • Aurobindo Pharma - Financial Result Updates

    6 Feb 2025, 7:51PM Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Aurobindo Pharma - Board Meeting Outcome for Outcome Of The Board Meeting Held On February 6, 2025

    6 Feb 2025, 7:48PM Intimation of outcome of the Board meeting held on February 6, 2025
  • Aurobindo Pharma - Outcome of Board Meeting

    6 Feb 2025, 7:43PM Aurobindo Pharma Limited has informed the Exchange regarding Board meeting held on February 06, 2025.
  • Aurobindo Pharma - Action(s) initiated or orders passed

    5 Feb 2025, 12:11PM Aurobindo Pharma Limited has informed the Exchange about Action(s) initiated or orders passed
  • Aurobindo Pharma - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    5 Feb 2025, 12:05PM Intimation of order received from Additional Commissioner of Central Tax , Ranga Reddy Commissionerate, Hyderabad
  • Aurobindo Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Feb 2025, 4:51PM Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
  • Aurobindo Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Feb 2025, 4:47PM Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Feb 2025, 4:43PM Intimation of investor meet to be held on 13.02.2025.
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Feb 2025, 4:40PM Intimation of Investor meet to be held on 12.02.2025.
  • Aurobindo Pharma - Press Release

    31 Jan 2025, 6:44PM Aurobindo Pharma Limited has informed the Exchange regarding a press release dated January 31, 2025, titled ""CuraTeQ Biologics s.r.o, receives positi
  • Aurobindo Pharma - Press Release - Curateq Biologics S.R.O, Receives Positive Opinion From CHMP / EMA For Dyrupeg

    31 Jan 2025, 6:41PM Press Release - Curateq Biologics s.r.o receives positive opinion from CHMP / EMA for Dyrupeg.
  • Aurobindo Pharma - Action(s) taken or orders passed

    29 Jan 2025, 11:33AM Aurobindo Pharma Limited has informed the Exchange about Action(s) taken or orders passed
  • Aurobindo Pharma - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    29 Jan 2025, 11:29AM Intimation of Two Orders received from Deputy Commissioner Punjagutta, Hyderabad under CGST Act and TGST Act.
  • Aurobindo Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    28 Jan 2025, 11:45AM Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
  • Aurobindo Pharma - Updates

    28 Jan 2025, 9:58AM Aurobindo Pharma Limited has informed the Exchange regarding 'Unit 2 of Apitoria Pharma Pvt. Ltd., received EIR from US FDA with VAI classification '.
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    28 Jan 2025, 11:41AM Intimation of Earnings Call to be held on February 7, 2025 at 08.30 AM (IST)
  • Aurobindo Pharma - Unit 2 Of Apitoria Pharma Pvt. Ltd., Received EIR From US FDA With VAI Classification

    28 Jan 2025, 10:01AM This is to inform you that Unit 2 of Apitoria Pharma Pvt.Ltd., received EIR from USFDA with VAI classification.
  • Aurobindo Pharma - Board Meeting Intimation

    17 Jan 2025, 12:06PM AUROBINDO PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 06-Feb-2025 to inter-alia consider and approve the Unaudited Fina
  • Aurobindo Pharma - Board Meeting Intimation for Intimation Of Board Meeting

    17 Jan 2025, 11:59AM AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 ,inter alia, to consider an
  • Aurobindo Pharma has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    13 Jan 2025, 6:10PM As of December 2024, 51.82% is owned by Promoters and 48.18% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 48.75% and F
  • Aurobindo Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    6 Jan 2025, 10:52AM Aurobindo Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Aurobindo Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    6 Jan 2025, 10:48AM Submission of certificate under regulation 74(5) OF SEBI (DP) Regulations, ,2018 for the quarter ended 31.12.2024.
  • Aurobindo Pharma - Updates

    28 Dec 2024, 2:47PM Aurobindo Pharma Limited has informed the Exchange regarding ''.
  • Aurobindo Pharma - Warning Letter Received From NSE With Regard To Corporate Announcements Submitted In Letter Head Of The C

    28 Dec 2024, 2:51PM Submission of warning letter received from NSE with regard to corporate announcements submitted in letter head of the Company where-in PAN of the Comp
  • Aurobindo Pharma - Loss/Duplicate-Share Certificate-XBRL

    27 Dec 2024, 5:38PM AUROBINDO PHARMA LIMITED has informed the Exchange about Loss of share certificates
  • Aurobindo Pharma - Loss of Share Certificates

    27 Dec 2024, 5:35PM Aurobindo Pharma Limited has informed the Exchange about Loss of Share Certificates
  • Aurobindo Pharma - Trading Window-XBRL

    25 Dec 2024, 3:48PM AUROBINDO PHARMA LIMITED has informed the Exchange about Closure of Trading Window
  • Aurobindo Pharma - Trading Window

    25 Dec 2024, 3:16PM Aurobindo Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,
  • Aurobindo Pharma - Press Release

    21 Dec 2024, 12:16PM Aurobindo Pharma Limited has informed the Exchange regarding a press release dated December 21, 2024, titled ""CuraTeQ Biologics receives approval for
  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    21 Dec 2024, 12:36PM Submission of Press Release that is being issued announcing that Curateq Biologics s.r.o, a wholly owned step down subsidiary of the Company has obtai
  • Aurobindo Pharma - Loss/Duplicate-Share Certificate-XBRL

    17 Dec 2024, 6:04PM AUROBINDO PHARMA LIMITED has informed the Exchange about Loss of share certificates
  • Aurobindo Pharma - Loss of Share Certificates

    17 Dec 2024, 6:03PM Aurobindo Pharma Limited has informed the Exchange about Loss of Share Certificates
  • Aurobindo Pharma - General Updates

    17 Dec 2024, 5:57PM Aurobindo Pharma Limited has informed the Exchange about General Updates
  • Aurobindo Pharma - Completion Of US FDA Inspection At Unit V Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of

    17 Dec 2024, 5:53PM Completion of US FDA Inspection at Unit V of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company
  • Aurobindo Pharma

    19 Feb 2025 , 10:27AM The US FDA concluded a pre-approval inspection at the company’s Andhra Pradesh unit with five observations.
  • Aurobindo Pharma

    14 Feb 2025 , 10:03AM The European Commission (EC) granted marketing authorization in EU for Zefylti, a bio-similar. Positive
  • Aurobindo Pharma

    23 Dec 2024 , 12:03PM Subsidiary CuraTeQ Biologics received marketing authorisation for Bevqolva, its bevacizumab biosimilar version in the UK. Positive
  • Aurobindo Pharma

    16 Dec 2024 , 1:06PM The company's arm CuraTeQ Biologics announced that the committee for medicinal products for human use within the European Medicines Agency has adopted a positive opinion for Zefylti (BP13, a filgrastim biosimilar), recommending the granting of a marketing authorisation.
  • Aurobindo Pharma

    6 Dec 2024 , 10:07AM Says unit Eugia gets final approval from U.S. FDA to manufacture & market Pazopanib Tablets; Co expect to launch in 4Q FY25.
  • Aurobindo Phama

    3 Oct 2024 , 1:34PM Company secures FDA nod for Cephalexin tablets to treat infections
  • Aurobindo Pharma

    1 Oct 2024 , 11:59AM USFDA issued 10 observations to company's API manufacturing facity in Telangana.
  • Aurobindo Pharma

    19 Sep 2024 , 10:58AM Aurobindo Pharma : US FDA issues EIR for arm Eugia Steriles’ new injectible unit at Parawada Mandal, Andhra Pradesh
  • Stock Update: Aurobindo Pharma

    20 Aug 2024 , 12:05PM Stock Update: Aurobindo Pharma – Eugia unit III WL to have no material impact on financials
  • Aurobindo down as USFDA issues warning letter

    16 Aug 2024 , 11:12AM Aurobindo Pharma falls after Eugia unit-III gets USFDA warning letter
  • Aurobindo Pharma

    16 Aug 2024 , 11:08AM The Unit-III, a Formulation manufacturing facility of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, receiving Official Action Indicated (OAI) status by the US FDA. Subsequent to OAI, the unit has received a Warning Letter. There is no impact on the existing supplies to the US markets. (Neutral)
  • Aurobindo Pharma

    7 Aug 2024 , 9:38AM Autobindo Pharma Ltd. reported that it has received final approval from the US Food and Drug Administration to manufacture and market estradiol vaginal. The company said their estradiol vaginal inserts have been developed with the treatment of atrophic vaginitis due to menopause in mind. The firm said that their product is "bioequivalent and therapeutically equivalent to the reference listed drug, VAGIFEM, of Novo Nordisk Inc.". The product will be launched in the second quarter of fiscal 2025. The product has an estimated market size of $268 million for the twelve months ending June 2024, according to IQVIA. Positive
  • Aurobindo Pharma

    6 Aug 2024 , 10:35AM The United States Food and Drug Administration (US FDA) had conducted an inspection at Unit[1]II, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Bhiwadi, Alwar, Rajasthan, from April 25th to May 3rd 2024. Subsequently, the US FDA has determined the inspection classification status of this facility as ‘Official Action Indicated (OAI). (Negative)
  • Aurobindo Pharma

    18 Jul 2024 , 9:47AM The board of directors approved the buyback of up to 51,36,986 (fifty one lakh thirty six thousand nine hundred eighty six only) fully paid-up equity shares of the Company, each having a face value of INR 1/- (Indian Rupee one only) (“Equity Shares”), representing up to 0.88% of the total number of equity shares in the paid-up equity share capital of the Company, at a price of INR 1,460/- (Indian Rupees fourteen hundred sixty only) per Equity Share (“Buyback Price”) payable in cash for an aggregate amount up to INR 750,00,00,000/-(Indian Rupees seven hundred fifty crores only) (“Buyback Size”) being 3.84% and 2.67% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2024, respectively. Positive
  • Aurobindo Pharma to consider share buyback on July 18

    15 Jul 2024 , 9:59AM Board Meeting on July 18, to consider buyback of shares
  • Aurobindo Pharma

    15 Jul 2024 , 9:16AM A meeting of the Board of Aurobindo Pharma will be held on Thursday, July 18, 2024 to consider, inter alia, a proposal for buyback of the fully paid-up equity shares of the Company and the matters necessary and incidental thereto, in accordance with the applicable provisions under the Companies Act, 2013. (Positive)
  • Stock update – Aurobindo Pharma

    29 May 2024 , 12:34PM Stock update – Aurobindo Pharma - USFDA issue escalates – Downgrade to Reduce
  • Aurobindo Pharma

    8 Apr 2024 , 11:54AM The new injectable facility of Eugia Steriles Private Limited situated at Parawada Mandal, Anakapalli District, Andhra Pradesh, has recently started the commercial operations. The United States Food and Drug Administration inspected the above-mentioned facility from March 28, 2024 to April 05, 2024 and the inspection closed with 3 observations. The observations are procedural in nature and will be responded to within the stipulated time. (Neutral)
  • Aurobindo Pharma

    1 Apr 2024 , 1:17PM Aurobindo Pharma Limited has commissioned four state-of-the-art manufacturing facilities for PenicillinG, 6-Amino Penicillanic Acid (6-APA), Injectable products and Granulation, through its wholly owned subsidiaries. (Positive)
  • Aurobindo Pharma

    20 Mar 2024 , 12:12PM Aurobindo Pharma gets US FDA approval for Mometasone Furoate Monohydrate Nasal Spray 50 mcg/spray.
  • Aurobindo Pharma

    20 Mar 2024 , 9:59AM The company received final approval from USFDA to manufacture and market Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nasonex Nasal Spray, 50 mcg/spray of Organon LLC. The product will be launched in Q1FY25. The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024, according to IQVIA.
  • Aurobindo Pharma

    18 Mar 2024 , 11:29AM CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Ltd, announced that their Omalizumab biosimilar candidate BP11 has met the Phase 1 trial end points of EU and US sourced reference product Xolair. The PK/PD trial was conducted in 165 healthy volunteers in Australia and New Zealand. Positive.
  • Aurobindo Pharma

    13 Mar 2024 , 10:25AM Eugia Pharma Specialities Ltd. has started distribution of aseptic products manufactured at Unit III, which was temporarily stopped. We also expect to start commercial production from the aseptic lines of the said facility in a phased manner beginning next week and to re-start all the lines by April 15, 2024. (Positive).
  • Aurobindo Pharma

    12 Mar 2024 , 9:53AM The Prequalification Unit Inspection Team of World Health organization (WHO) had conducted an inspection at the Unit IV, a Formulation manufacturing facility, of APL Healthcare Limited, a wholly owned subsidiary of the Company, situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from September 11 to September 15, 2023. Based on the inspection findings and our response to the same, the PQT-INS has decided to recommend to the Prequalification Assessment Team that the above facility be named as a manufacturing site in the dossier for Dolutegravir, Lamivudine, Tenofovir Disoproxil Fumarate Tablets (50/300/300 mg).Positive
  • Aurobindo Pharma

    1 Mar 2024 , 12:35PM Eugia Pharma Specialities Limited has restarted production in its terminally sterilized product lines at its Unit-III, that was temporarily stopped to address some of the observations of USFDA in their recent inspection concluded on 2nd February 2024. We expect to start the production in the aseptic lines of the facility in the month of March 2024. The United States Food and Drug Administration (US FDA) inspected the injectable facility of Eugia situated at Polepally Village, Jadcherla Mandal from 19th to 29 th February 2024. The inspection closed with 7 observations. The observations are procedural in nature and will be responded to within the stipulated time. (Negative)
  • Aurobindo Pharma

    16 Feb 2024 , 2:37PM The manufacturing unit of Auro Peptides Ltd, the synthetic peptides API business arm of the company, situated at Indrakaran Village, Kandi Mandal, Sangareddy District, Telangana, was audited by the US FDA from 12th to 16th February 2024. The inspection was concluded with zero observations. (Positive)
  • Aurobindo Pharma

    5 Feb 2024 , 10:08AM US FDA inspected Unit-III, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Pashamylaram, Patancheru Mandal, Sangareddy District, Telangana, from 22 nd January to 2 nd February 2024. The inspection closed with 9 observations. The company has decided to temporarily stop manufacturing on certain lines to conduct holistic investigation and corresponding partial distribution thereto. The company has already started working with the regulatory authority / third party consultants to accelerate the process and re-start production on those lines at the earliest. At this point in time, the company don’t foresee any material impact on the business.
  • Aurobindo CDSCO recommends granting marketing nod for Biosimilar Trastuzumab to CuraTeQ Bio

    17 Jan 2024 , 12:09PM CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab'
  • Aurobindo Pharma

    11 Jan 2024 , 10:00AM Aurobindo Pharma - is in value unlocking mode again, and is now exploring a big-bang initial public offer (IPO) of its wholly-owned subsidiary — speciality generic firm Eugia Pharma Specialities — to raise around Rs 4,500 crore in 2024, multiple industry sources told Moneycontrol. With the markets in a buoyant phase and pharma valuations looking attractive, Aurobindo Pharma is now evaluating a listing of Eugia. The deal was kicked off recently with all the advisors. (Positive)
  • Aurobindo Pharma

    9 Jan 2024 , 9:58AM The U.S. Food and Drug Administration (FDA) had conducted an inspection at the Unit VI-B, a Formulation manufacturing facility of the Company, situated at Chitkul Village, Patancheru Mandal, Sangareddy ,Telangana, from September 22 to September 29, 2023. The Unit has now received Establishment Inspection Report classifying the facility as "Voluntary Action Indicated" ("VAI"). Stock in Focus.
  • Aurobindo Pharma

    27 Dec 2023 , 11:35AM Aurobindo’s wholly owned subsidiary company, Eugia Pharma Specialities Limited, has received final approval from the US Food & Drug Administration to manufacture and market Posaconazole Injection, 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Noxafil Injection, 300 mg/16.7 mL (18 mg/mL), of Merck Sharp & Dohme LLC (Merck). The product is expected to be launched in December 2023. The approved product has an estimated market size of US$ 25.4 million for the twelve months ending October 2023, according to IQVIA. (Positive)
  • Aurobindo Pharma

    26 Dec 2023 , 11:09AM The US FDA had conducted a Pre-Approval Inspection at new injectable facility of Eugia USA from December 11 to December 22, 2023. The inspection closed with 10 observations. The observations are procedural in nature and will be responded to within the stipulated time. The plant is yet to start commercial operations. (Negative)
  • Aurobindo Pharma arm Eugia Pharma gets USFDA nod for Budesonide Inhalation suspension

    30 Nov 2023 , 11:32AM Budesonide Inhalation Suspension is used to treat asthma in children
  • Aurobindo Pharma gets final USFDA nod for Darunavir tablets

    29 Nov 2023 , 11:59AM Aurobindo Pharma gets final US FDA approval for Darunavir tablets, used with other medications to help control HIV Infection
  • Aurobindo Pharma

    20 Nov 2023 , 11:42AM The United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection (PAI) at Unit-I & III, Formulation manufacturing facility, of APL Healthcare Ltd., a wholly owned subsidiary of the Company, situated at TSIIC Green Industrial Park, Pollepally Village, Jedcharla Mandal, Mahabubnagar District, Telangana, 509302, from November 13 to 17, 2023. The inspection closed with zero observations and a classification of “No Action Indicated” (NAI). (Positive)
  • Aurobindo Pharma

    23 Oct 2023 , 1:47PM Eugia Pharma receives USFDA Approval for Testosterone Cypionate Injection USP 1,000 mg/10 mL (100 mg/mL) and 2,000 mg/10 mL (200 mg/mL) in Multi-Dose Vial and 200 mg/mL in Single-Dose Vial. Testosterone Cypionate Injection USP is indicated replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone, Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired). This is the 169 th ANDA approval (including 9 tentative approvals received) out of Eugia Pharma Speciality Group (EPSG) facilities, manufacturing both oral and sterile specialty products. (Positive)
  • Aurobindo Pharma

    12 Oct 2023 , 10:33AM CuraTeQ Biologics Private Limited (“CuraTeQ”), a wholly owned subsidiary of the Company, along with its subsidiary has been in discussions with Merck Sharp & Dohme Singapore Trading Pte. Ltd. and its affiliates (“MSD”) for CMO operations and in this regard the parties have signed a limited Letter of Intent (“LOI”). CuraTeQ proposes to serve the US-based biopharmaceutical company through its contract manufacturing subsidiary, TheraNym Biologics Pvt Ltd. Further, in the interest of time and project needs, CuraTeQ will place orders for certain long-lead equipment and also begin civil works of the manufacturing facility.
  • Aurobindo Pharma

    28 Sep 2023 , 10:33AM Auro Vaccines Private Limited, a wholly owned subsidiary of the Company, has entered into a Licence Agreement with Hilleman Laboratories Singapore Pte. Limited to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination. Auro Vaccines Private Limited will make milestone payments to Hilleman upon achieving certain development and clinical study outcomes. Hilleman will also be paid royalties upon commercialization of the vaccine candidate.
  • Aurobindo Pharma

    17 Aug 2023 , 10:34AM The company along with its subsidiaries, has announced a tentative approval from the USFDA under the PEPFAR program for the first generic dispersible tablet formulation of the fixed dose combination Abacavir 60mg + Lamivudine 30 mg + Dolutegravir 5 mg (pALD), for the treatment of children living with HIV weighing 6 kg to <25 kg and aged at least 3 months. Aurobindo has a paediatric dolutegravir voluntary licence with ViiV Healthcare, enabling development and supply of this product in 123 Low and Middle-Income Countries (LMIC), including India. This is one of the fastest approvals for a generic combination product following approval of the innovator formulation, with ViiV having secured USFDA approval in March 2022. Aurobindo’s product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon. Positive for the stock.
  • Aurbindo Pharma unit gets USFDA nod for Icatibant Injection

    16 Aug 2023 , 5:05PM Aurobindo Pharma arm gets USFDA nod for Icatibant Injection used for the treatment of sudden attacks of Hereditary Angioedema
  • Aurobindo Pharma

    7 Aug 2023 , 11:02AM Aurobindo Pharma informed that its wholly owned subsidiary, Eugia Pharma Specialities Ltd., has received final approval from the USFDA to manufacture and market Vancomycin Hydrochloride for Injection USP, 1.25 g/vial and 1.5 g/vial, Single-Dose Vial, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vancomycin Hydrochloride for Injection USP, by Mylan Laboratories Ltd. The product is being launched in August 2023. The approved product has an estimated market size of around USD 34.4 million for the twelve months ending May 2023, according to IQVIA. Positive for the stock.
  • Aurobindo Pharma

    2 Aug 2023 , 10:39AM Aurobindo Pharma received USFDA approval for Saxagliptin tablets (diabetic drug) 2.5 and 5.0 mg, which is a generic of RLD Onglyza tablets 2.5 and 5.0 mg of AstraZeneca AB. Positive for the stock as Aurobindo is eligible for 180 days of shared generic drug exclusivity for Saxagliptin Tablets, 2.5 mg, and 5 mg. The product is being launched immediately. The annual sales for the product is USD 101 million as of June 2023.
  • Aurobindo Pharma

    27 Jul 2023 , 3:21PM Aurobindo Pharma has formed a step-down subsidiary called Auro Pharma LLC in Russia, which is the subsidiary of the company’s wholly owned subsidiary called Auro Active Pharma Ltd., with an initial investment of USD 10 million. Positive read through as it will pave the way for the company to explore business opportunity in fast growth Russia market.
  • USFDA issues zero observations for Aurobindo Pharma's Eugia Pharma Koltur unit

    26 Jul 2023 , 12:50PM USFDA inspect Eugia Pharma Koltur unit from July 17-26
  • Aurobindo Pharma

    26 Jul 2023 , 12:45PM Aurobindo Pharma informed that the USFDA inspection for its formulation’s facility at Eugia Pharma Specialties Ltd., a wholly owned subsidiary of the company, located at Telangana closed with zero observations. Positive
  • Aurobindo Pharma arm Eugia Pharma gets USFDA Nod for Plerixafor Injection

    25 Jul 2023 , 1:43PM Plerixafor is used in preparation for some autologous stem cell transplants
  • Aurobindo Pharma

    24 Jul 2023 , 12:20PM The USFDA inspected the company’s Unit III formulation manufacturing facility located at Bachupally Village, Telangana, from July 14 – July 21. The company has received form 483 with 3 observations. Negative.
  • Aurobindo Pharma

    17 Jul 2023 , 11:10AM Aurobindo Pharma Ltd.’s Unit XIV at Anakapalli district, Andhra Pradesh has now received EIR, classifying the facility as Voluntary Action Indicated (VAI). Positive for the stock.
  • Aurobindo Pharma

    10 Jul 2023 , 10:39AM The company’s unit CuraTeQ Biologics has inked exclusive licensing agreement with U.S. based BioFactura Inc. to sell BFI-751 biosimilar. BFI-751 is a proposed biosimilar Ustekinumab, which is a recombinant monoclonal antibody, sold under brand Stelera. It is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. BioFactura will get license fees of upto USD 33.5 million as well as CuraTeq will get profit sharing to the tune of 57%-60% with global manufacturing rights for Ustekinumab. Positive for Aurobindo.
  • Aurobindo Pharma

    5 Jul 2023 , 9:09AM Aurobindo Pharma Ltd. announced that its breast cancer biosimilar product BPO2 (Trastuzumab or biosimilar of Herceptin) being developed by its subsidiary called Curateq Biologics Pvt Ltd. has met its primary endpoint in Phase III clinical trial. BP02 has shown equivalent efficacy to Herceptin regarding its clinical response (overall response rate, ORR), in addition to demonstrating a comparable safety profile. CuraTeQ is in the process of initiating submissions to regulatory agencies starting in Q1FY24. The company hopes to complete market authorization (MA) application submissions across all key regulated markets in a phased manner, by March 2024. Its first submission will be in India in July 2023. Positive read through for the stock.
  • Aurobindo Pharma

    30 Jun 2023 , 9:51AM USFDA believes that Aurobindo Pharma's lapses were graver in quality terms than was stated earlier at Anaka Palli facility in India while the company had considered them to be procedural lapses in May 23. Negative red through for the stock.
  • Aurobindo Pharma

    26 Jun 2023 , 12:18PM Aurobindo Pharma’s subsidiary CuraTeQ Biologics s.r.o informed that European Medical Agency (EMA) has accepted its request for withdrawing application for ZEFYLTI (a filgrastim biosimilar) and DYRUPEG (a pegfilgrastim biosimilar)’s marketing authorization as the company is uncertain if it can get its biosimilar facility to obtain EU GMP certification within 180 days period and as that no more extensions are available for that deadline as of now. Sentimentally negative for the stock.
  • Aurobindo Pharma arm enters sub-licensing agreement with medicines patent pool

    23 Jun 2023 , 11:55AM Aurobindo arm enters sub-licensing agreement with medicines patent pool for Nilotinib Capsules to treat certain types of Chronic Myeloid Leukemia
  • Aurobindo Pharma

    23 Jun 2023 , 11:47AM Aurobindo Pharma’s subsidiary Eugia Pharma Specialities Ltd. (Eugia) has entered into a sub-licensing agreement with Medicine Patent Pool (MPP) to develop and market Nilotinib Capsules, originally developed by Novartis, for the treatment of chronic myeloid leukaemia (CML) or cancer in 44 Low and Middle-Income Countries (LMIC), including the seven countries where patents on the product are pending or in force. The product will be produced at the Eugia Pharma Specialities Ltd. Unit-I, Medchal, Malkajgiri District, Telangana, India. The company has adequate capacities to meet the global demand for the product across the licensed territory
  • Aurobindo Pharma

    6 Apr 2023 , 11:41AM Newly formed Antibiotic API subsidiary called Apitoria Pharma Pvt Ltd has got the new CEO called Dr. Sanjay Chaturvedi. He was working with IOL Chemicals and Pharma before, as the ED and CEO. Positive read through.
  • Aurobindo Pharma

    3 Apr 2023 , 1:27PM Aurobindo Pharma Ltd is to transfer units including antibiotic API division to its wholly owned subsidiary, Apitoria Pharma via slump sale for Rs 502.62 crore. Additionally, the board has approved the merger of two arms Auronext Pharma and Mviyes Pharma Ventures with the company. Neutral read through.
  • Aurobindo Pharma

    31 Mar 2023 , 12:23PM Aurobindo Pharma has signed a voluntary sub – licensing with Medicines Patents Pool (MPP), a UN organisation, for developing and marketing Cabotegravir tablets and long acting injectables, originally developed by ViiV Healthcare, for prevention of HIV in 90 low- and middle-income countries (LMIC) including India. Positive as this product will be a good addition to Aurobindo’s ARV portfolio.
  • Aurobindo Pharma

    8 Mar 2023 , 11:31AM Aurobindo Pharma announced that its subsidiary Eugia Pharma Specialties Ltd. has received final approval from the USFDA to manufacture and market Lenalidomide capsules in 2.5, 5, 10, 15, 20 and 25 mg, which is bioequivalent and therapeutically equivalent to the RLD Revlimid capsules of the same strengths. Positive read through for the stock.
  • Aurobindo Pharma arm gets final USFDA nod for Lenalidomide Capsules

    8 Mar 2023 , 11:13AM Aurobindo Pharma arm gets final USFDA nod for Lenalidomide Capsules, used to treat Anemia
  • Aurobindo Pharma

    17 Feb 2023 , 11:58AM Aurobindo Pharma's APL Healthcare Ltd.’s unit I and III, an oral (tablets, capsules, and soft gel capsules) and Derma manufacturing facilities located at Telangana, which were inspected by the USFDA from Jan 9 - Jan 18, 2023 have now been classified as Voluntary Action Indicated (VAI). Neutral to Marginally negative.
  • Aurobindo Pharma

    14 Feb 2023 , 12:02PM Aurobindo Pharma’s Unit IX, an API intermediate facility located at Gundlamachnoor Village, Telangana, which was inspected by the USFDA from November 10 – November 18, 2022 has been classified as a Voluntary Action Indicated (VAI). Marginally negative to neutral read through for the stock.
  • Aurobindo Pharma

    8 Feb 2023 , 10:07AM Aurobindo Pharma announced that its step-down subsidiary, Aurolife Pharma LLC, has received a final approval from the USFDA to manufacture and market Diclofenac Sodium Topical Solution USP, which is bioequivalent and therapeutically equivalent to reference listed drug (RLD) Pennsaid Topical Solution of Horizon Ireland DAC (Horizon). The product is expected to be launched in Q1FY2024. The approved product has an estimated market size of USD 487 million for LTM ending December 2022. Positive read through for the stock.
  • Aurobindo Pharma

    19 Jan 2023 , 9:48AM Aurobindo Pharma informed that the USFDA post inspecting its subsidiary, APL Health Care Ltd.’s Unit I and III, an orals and derma manufacturing facility located at Telangana, issued form 483 with 2 observations
  • Aurobindo Pharma

    4 Jan 2023 , 12:17PM The company has received a final approval from the USFDA to manufacture and market Azacitidine for injection 100 mg single dose vial as a bioequivalent to the Reference Listed Drug (RLD) Vidaza for injection, 100 mg single dose vial of Bristol Myers Squibb Company. The product is likely be launched in January 2022 and has an estimated market size of around USD 46 million for LTM ended November 2022, according to IQVIA. Our view: Marginally positive for the stock
  • Aurobindo Pharma arm Eugia Pharma gets USFDA nod for Azacitidine injection

    4 Jan 2023 , 11:47AM Eugia Pharma receives USFDA approval for Azacitidine for Injection
  • Aurobindo Pharma

    16 Dec 2022 , 10:46AM Court has accepted CBI Chargesheet in Delhi liquor case and has issued summons to all accused as per media reports. The name of the Aurobindo Pharma's Director Sharath Reddy has been missing from the chargesheet though. Our view: Positive for the stock.
  • Aurobindo Pharma

    16 Dec 2022 , 10:45AM Aurobindo Pharma: Court has accepted CBI Chargesheet in Delhi liquor case and has issued summons to all accused as per media reports. The name of the Aurobindo Pharma's Director Sharath Reddy has been missing from the chargesheet though. Our view: Positive for the stock.
  • Eugia Pharma receives USFDA Approval for Amphotericin B Liposome for Injection

    18 Nov 2022 , 10:52AM Aurobindo Pharma arm Eugia Pharma gets USFDA nod for Amphotericin B Liposome Injection used to treat fungal infections
  • Eugia Pharma receives USFDA Approval for Amphotericin B Liposome for Injection.

    18 Nov 2022 , 10:41AM Aurobindo Pharma arm Eugia Pharma gets USFDA nod for Amphotericin B Liposome Injection used to treat fungal infections
  • Aurobindo Pharma

    17 Nov 2022 , 1:25PM Aurobindo Pharma
  • Aurobindo Pharma

    10 Nov 2022 , 10:22AM According to media reports, the Enforcement Directorate has arrested Sharath Reddy (Director of Aurobindo Pharma) for money laundering in connection with the Delhi liquor policy case. The stock has already reacted negatively to the news.
  • Aurobindo Pharma

    28 Sep 2022 , 10:36AM The company has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application dicloxacillin sodium capsules USP, 250mg and 500mg. Dicloxacillin sodium capsules are indicated for the treatment of infections caused by penicillinase-producing staphylococci, which have demonstrated susceptibility to the drug. Dicloxacillin sodium capsules has an estimated market size of US $5.3 Million for the twelve months ending July 2022, as per IQVIA – Positive read through for the stock
  • Aurobindo Pharma

    22 Sep 2022 , 1:11PM The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company, has received an establishment inspection report (EIR) mentioning that the inspection a voluntary action initiated (VAI) from the United States Food and Drug Administration (US FDA) and with this, the US FDA pre-approval inspection and GMP inspection are concluded.
  • Aurobindo Pharma

    22 Sep 2022 , 12:01PM The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company, has received an establishment inspection report (EIR) mentioning that the inspection a voluntary action initiated (VAI) from the United States Food and Drug Administration (US FDA) and with this, the US FDA pre-approval inspection and GMP inspection are concluded.
  • Aurobindo Pharma's North Carolina units gets establishment inspection reports from USFDA

    22 Sep 2022 , 11:48AM Completion of US FDA Inspection at Raleigh Plant, North Carolina, owned by Aurolife Pharma LLC
  • Aurobindo Pharma gets USFDA nod for Medroxyprogesterone Acetate injectable suspension

    24 Aug 2022 , 10:57AM The product will be launched in Q3 FY23
  • Aurobindo Pharma arm Eugia Pharma receives USFDA nod for Vasopressin Injection USP

    16 Aug 2022 , 9:51AM Eugia Pharma receives USFDA Approval for Vasopressin Injection USP
  • Aurobindo Pharma

    20 Jul 2022 , 9:49AM Aurobindo: The company gets USFDA approval for Famotidine , which is used to treat heartburn due to acid indigestion and sour stomach caused by eating or drinking certain foods or drinks. Positive
  • Aurobindo Pharma

    11 Jul 2022 , 10:55AM The company pulled out of the proposed sale of Eugia Pharma, which is the injectables arm of the company. Eugia pharma consists of general injectable, oncology injectable, oncology oral solids, and hormonals business. The deal was called off citing valuation differences as the promoter family has valued the business at around Rs 26000 to RS 30000 crore , translating to $3-4 bn. The bid ask difference was quiet large and hence the deal was called off. Negative Read thru
  • Aurobindo Pharma

    6 Jul 2022 , 1:13PM Aurobindo: The company’s wholly owned subsidiary - Eugia Pharma gets USFDA final approval for Triamcinolone Acetonide Injectable Suspension strength - 200 mg/5 ml & 400 mg/10 ml. the drug is indicated for the treatment of Intramuscular and Intra-Articular use. In intra muscular use its indicated for allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases and rheumatic disorders, while for Intra-Articular - adjunctive therapy for acute gouty arthritis, acute and subacute bursitis and rheumatoid arthritis amongst others. The drug would be launched in the US markets in this month and has an indicative market size of $73 mn for the recent 12 months ending May 2022; Positive
  • Aurobindo Pharma arm gets USFDA nod for Triamcinolone Acetonide injectable suspension

    6 Jul 2022 , 12:14PM Eugia Pharma receives USFDA Approval for Triamcinolone Acetonide Injectable Suspension
  • Aurobindo Pharma

    5 Jul 2022 , 12:40PM The board of directors on 28th March 2022 had announced the approval for acquisition of business and certain assets of Veritaz Healthcare Limited, which is an India focused pharmaceutical company selling branded formulations. The acquisition is done for a consideration of Rs 171 crore and is within the purview of a related party transaction. Now Aurobindo has announced the closure of the transaction
  • Aurobindo Pharma

    20 Jun 2022 , 10:40AM Aurobindo: The board of the company has approved to acquire a 51% stake in the GLS Pharma operating in oncology business and having manufacturing facility in Hyderabad for a total consideration of Rs 28.05 cr. GLS Pharma engaged in oncology products which include orals and injectables used in chemotherapy for solid malignancies, chemotherapy for hematological malignancies and chemo supportive products and has a presence in India only. The company was incorporated in September 2004 and since then has been operational in India Markets. Arobindo has an option to call to acquire the balance 49% stake after 3 years and before 5 years.
  • Aurobindo Pharma

    15 Jun 2022 , 10:00AM As per media news, the company gets tentative US-FDA nod for Brivaracetam, used to control partial-onset seizures. Approval is positive as it would add to the product offering upon receipt of final approval, in the US markets which accounts for almosyt half of the company’s revenues.
  • Sun Pharma, Aurobindo

    10 Jun 2022 , 10:23AM Sun Pharma’s Arm Teva has reached an agreement with Aurobindo to resolve the dispute over Aurobindo’s ANDA for a generic deutetrabenazine product. Teva and Aurobindo have been involved in a patent infringement litigation in which Teva asserted a number of patents against Aurobindo that cover Teva’s AUSTEDO (deutetrabenazine) product. As per the settlement agreement, Aurobindo would have a license to sell its generic product beginning April 2033 or earlier under certain circumstances. Positive read thru for Sun Pharma as Teva would continue to sell its product while for Aurobindo it would remove the overhang.
  • Aurobindo Pharma arm gets USFDA nod for Leuprolide Acetate injection

    7 Jun 2022 , 11:57AM Leuprolide Acetate injection is used to treat endometriosis
  • Aurobindo Pharma arm gets USFDA nod for Leuprolide Acetate injection

    7 Jun 2022 , 11:57AM Leuprolide Acetate injection is used to treat endometriosis
  • Aurobindo Pharma arm gets USFDA nod for Leuprolide Acetate injection

    7 Jun 2022 , 11:57AM Leuprolide Acetate injection is used to treat endometriosis
  • Aurobindo gets USFDA nod for Naproxen Pseudoephedrine drug for US markets

    6 Jun 2022 , 10:07AM Aurobindo Pharma gets USFDA nod for Naproxen, Pseudoephedrine drug, used to treat aches, pains, and congestion of cold
  • Aurobindo Pharma

    6 Jun 2022 , 9:36AM Aurobindo: The company gets USFDA approval for Naproxen Pseudoephedrine drug for US markets. This is a combination drug which is indicated for treatment of aches, pains, and congestion of cold. The approval is positive as would widen the Product portfolio in the US which constitutes around half of the company’s revenues.
  • Aurobindo Pharma arm gets USFDA approval for Pemetrexed injection

    26 May 2022 , 11:13AM Eugia Pharma receives USFDA Approval for Pemetrexed for Injection
  • Aurobindo Pharma

    19 May 2022 , 9:06AM Aurobindo: Gets USFDA approval for Nicotine Polacrilex Lozenges, whichis used to enable people quit smoking. Also the company’s unit 5 has received an Establishment Inspection Report after the management has submitted its responses to the USFDA following a Form 483 with 5 observations being issued after the pre approval inspection in February 2022. The new product approval as well as EIR for unit 5 are positive for Aurobindo
  • Aurobindo Pharma

    11 May 2022 , 9:14AM Aurobindo: The USFDA has inspected the company’s unit VII, which is an oral manufacturing plant located at Hyderabad between 2nd to 10th May 2022. The inspection ended with a form 483 being issued by the USFDA with 6 observations. The management expects to submit the responses to these observations with in stipulated time line. The Receipt of the Form 483 with 6 observations is negative.
  • Aurobindo Pharma

    29 Mar 2022 , 9:42AM Aurobindo: Board of Directors approved the acquisition of business and certain assets of Veritaz Healthcare Limited, which is an India focused pharmaceutical company selling branded formulations. The acquisition is done for a consideration of Rs 171 crore and is within the purview of a related party transaction. We await further clarity on this. Aurobindo has entered in to a definitive agreement to acquire business and certain assets of Veritaz Healthcare Limited. Veritaz operates in pharmaceutical industry in India and sells branded generic formulations and other health care related products. It has around 180 trademarks, off which 40 are marketed. Veritaz derives majority of its revenues from the Pain management as well as anti infective segments and has around 700 sales representatives and 1700 stockists pan india. Veritaz has reported sales of Rs 127 cr and Rs 133.18 cr for FY21 and 9MFY22 respectively while it has reported EBITDA of Rs 0.47 cr and Rs 13.09 cr over the same period, translating to OPM’s of 0.4% and 9.8% respectively.
  • Aurobindo Pharma

    23 Mar 2022 , 12:22PM Aurobindo: as per media news the company is closing its Aurolife (New Jersey) plant in the US in the next month. Aurolife is a step down subsidiary of company (fully owned by subsidiary company Aurobindo Pharma USA). The company derives around half of its revenues from the US geography and closure of the plant could slow down the new fillings as the company had filled products through Aurolife. Negative read thru .
  • Stock Update - Aurobindo Pharma

    11 Feb 2022 , 12:05PM Stock Update - Aurobindo Pharma Limited: Weak Q3; improved outlook
  • Aurobindo Pharma Q2FY22: Weak Quarter

    10 Feb 2022 , 12:15PM Aurobindo Pharma Q2FY22: Weak Quarter; operating profits miss estimates due to higher costs
  • Aurobindo Pharma

    14 Jan 2022 , 11:17AM The USFDA post its inspection of the company’s unit 1, Hyderabad (API facility) had classified it as an OAI in November 2021. Further the USFDA has issued a warning letter to the facility and the management believes that the warning letter could not impact the existing business from this facility. The Company will be engaging with the regulator and is fully committed in resolving the same. Receipt of the Warning Letter is negative
  • Aurobindo Pharma's Hyderabad API unit gets warning letter from USFDA

    14 Jan 2022 , 9:54AM Aurobindo Pharma's Hyderabad unit issued a warning letter following recent inspection, by USFDA in August 2021
  • Aurobindo Pharma

    11 Jan 2022 , 2:29PM Aurobindo: The company has appointed Kotak Mahindra Capital to find a buyer for its injectables business. The company is in talks with private equity funds to sell a stake of around 30-35% in its injectable business for Rs 4500-5250 crore ($600-700 million), this valuing the injectables business at RS 15000 cr. The move is in line with the company’s value unlocking plans. Positive read thru.
  • Aurobindo Pharma

    11 Jan 2022 , 12:47PM Aurobindo: Wholly owned subsidiary company - CuraTeQ Biologics Pvt Ltd has expanded the scope of its marketing and distribution agreement with Orion Corporation (Orion) to commercialize its biosimilars pipeline to include the Baltic states in Europe. The earlier agreement granted marketing rights in Nordic states, Austria, Hungary and Slovenia. CuraTeQ had filed its first biosimilar product with EMA in September 2021 and now on 10th January 2022 has filed the second biosimilar product, with both the products in the oncology space. Extension of marketing agreement and filling of the second biosimilar product is potential positive
  • Aurobindo Pharma's arm CuraTeq and Orion expand licensing deal for marketing & distribution

    11 Jan 2022 , 12:08PM CuraTeQ and Orion expand licensing deal for biosimilars distribution in select European markets
  • Aurobindo Pharma

    7 Jan 2022 , 2:00PM Launches their version of Molnupiravir under its brand name Molnaflu, which provides an affordable option for treatment of Covid -19. Given the increase in the cases the demand is expected to be strong, but with several players getting approval for the drug, we believe the size opportunity could moderate. Positive read thru
  • Aurobindo Pharma

    7 Jan 2022 , 2:00PM Launches their version of Molnupiravir under its brand name Molnaflu, which provides an affordable option for treatment of Covid -19. Given the increase in the cases the demand is expected to be strong, but with several players getting approval for the drug, we believe the size opportunity could moderate. Positive read thru
  • Aurobindo Pharma

    3 Jan 2022 , 10:37AM The company has transferred its Unit 18, which is engaged in the Vaccines manufacturing to its newly incorporated wholly owned subsidiary – Auro Vaccines Private Limited. The agreement was entered in to on 1 January 2022 and the transaction is likely to completed by Q4FY22. The transfer of the business undertaking is done on a lumpsum consideration of Rs 299 crore. The transfer of the business unit is done with an objective of Segregation of the vaccines business in a verticalized manner, impriving operational efficiency and to achieve flexibility for value creation opportunities including exploration of alliances with focused partners to enhance capabilities/growth prospects in vaccines business. Also the board of directors have appointed Mr K Nithyananda Reddy, who is a part of the promoter family, as the Vice Chairman and Managing Director of the company effective 1st January 2022. Potential positive
  • Aurobindo Pharma

    22 Dec 2021 , 10:11AM Aurobindo: Gets USFDA approval for Bystolic Tablets, which are indicated to treat patients with high blood pressures or hyper tension along with other medicines. As per media reports the market size for Bystolic tablets 2.5 mg, 5 mg, 10 mg, and 20 mg strengths is approximately $1.05 billion as of September 2021, according to IQVIA/IMS Health, which is substantial. Positive
  • Aurobindo Pharma

    23 Nov 2021 , 9:40AM As per media news the company has received an approval from the USFDA for its ANDA for Predisone tablets, which belongs to a class of drugs known as corticosteroids. The drug is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. The approval is positive and would add to the US revenues growth which account for half of the overall revenues of the company
  • Dr Reddys, Aurobindo, Strides Pharma, Natco Pharma

    18 Nov 2021 , 10:52AM As per media news, the Subject Matter Expert Committee (SEC) of the Indian Drug Regulator would be meeting up today (Thursday) to consider and examine accelerate approvals for MSD’s anti covid oral drug – Molnupiravir. The company’s whose application would be reviewed today include Dr Reddys along with others such as Hetero Labs, Natco Pharma, Aurobindo Pharma, Optimus Pharma, Strides Pharma, MSN Pharma and BDR Pharmaceuticals. Positive for these companies if Molnupiravir gets accelerated approval
  • Stock update: Aurobindo Pharma Q2Fy22 Results Review

    10 Nov 2021 , 11:23AM Stock update: Aurobindo Pharma Q2Fy22 Results Review - Weak quarter; Valuations reasonable
  • Aurobindo Pharma Q2FY22

    9 Nov 2021 , 10:17AM Aurobindo Pharma Q2FY22: Weak Quarter; Results miss estimates
  • Aurobindo Pharma

    30 Sep 2021 , 10:56AM French subsidiary Arrow Generiques SAS has announced the opening of its new logistics and industrial site in Saint Vulbas, near Lyon, France. The site is principally dedicated for the storage, preparation and distribution of pharmaceutical products with an additional unit built for future industrial activities. The site’s strategic location in the logistics hubs of the region is an advantage and could enable the company to support growth plans in the French markets, hence positive
  • Aurobindo Pharma's subsidiary submits biosimilar filing with EMA

    23 Sep 2021 , 10:46AM Aurobindo's subsidiary submit first biosimilar filing to European Medicines Agency
  • Aurobindo Pharma

    9 Sep 2021 , 9:44AM As per media news the company has received USFDA approval for anti-bacterial drug Daptomycin. The drug is used to treat certain blood infections or skin infections in adults as well as Children aged 1 year and older. The USFDA approval is positive and would add to the US revenue growth.
  • Aurobindo Pharma

    27 Aug 2021 , 10:24AM Aurobindo Pharma: Subsidiary company Eugia Pharma Specialties has received a 505(b)(2) NDA approval from the USFDA for its Cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vials. The product will be available in ready-to-use (RTU) injection preparation and shall be launched in the US markets in the near term. Cyclophosphamide Injection is indicated for Malignant lymphomas, Multiple myeloma, Leukemias, Mycosis fungoides, Neuroblastoma, retinoblastoma. The drug has an addressable market size of $170 mn in the US for the 12 months ending June 2021, which is sizeable and hence positive.
  • Aurobindo Pharma's subsidiary Eugia Pharma gets USFDA approval for its Cyclophosphamide Injection

    27 Aug 2021 , 9:01AM Eugia receives USFDA Approval for Cyclophosphamide Injection
  • Aurobindo Pharma

    23 Aug 2021 , 9:34AM Aurobindo: The board of directors have approved the termination of the agreement entered with Cronus Pharma limited to acquire a 51% stake for a consideration of Rs 420 crore. The acquisition of the said stake was at a higher valuation and the termination of the deal could remove the over hang on the stock.
  • Stock Update: Aurobindo Pharma

    16 Aug 2021 , 12:09PM Stock Update: Aurobindo Pharma Ltd - Weak quarter; Near term headwinds apparent
  • Aurobindo Pharma Q1FY22

    13 Aug 2021 , 10:43AM Aurobindo Pharma Q1FY22: Weak Quarter; Results marginally miss estimates
  • Aurobindo Pharma

    22 Jul 2021 , 10:30AM Aurobindo: Gets USFDA approval for Nifedipine tablet (strength 30-90 mg). The tablets are used for treatment of blood pressures and the approval is positive as it would add to the growth of the US sales, which constitute around half of the overall sales of the company.
  • Aurobindo Pharma

    2 Jul 2021 , 9:37AM The Board of Directors have approved the transfer of Unit 4 on a going concern basis to Eugia Pharma Specialties Limited, a wholly owned subsidiary company. Unit 4 as of March 2021 has reported a turnover of Rs 926.7 cr representing 5.86% of the standalone turnover and 3.7% of the consolidated turnover of the company. The sale is expected to be completed in Q2Fy22 and business transfer would be effective 1 July 2021. Transfer of the Business Undertaking will be done for a lumpsum consideration of Rs. 876 crores. With the transfer of Unit 4 Aurobindo’s all injectables business are now under – Eugia Pharma and this would bring in enhanced focus on the injectables business and also offers more flexibility for value unlocking opportunities if need be. Also Board has fixed the consideration for transfer of unit 10 (announced earlier) at RS 1315 crore and with this, the SEZ units of the company are now under its wholly owned subsidiary - APL Health care limited. We believe the above offers enhanced growth visibility as well as set a platform for possible value unlocking opportunities going ahead. We have a Buy rating on Aurobindo with a PT of RS 1185.
  • Aurobindo Pharma

    16 Jun 2021 , 2:01PM As per media news, the company to consider demerger of the injectable business. If the demerger process goes through it could provide value unlocking opportunities to the existing shareholders and hence positive
  • Aurobindo Pharma Limited: Q4FY2021 Result Update

    1 Jun 2021 , 12:12PM Aurobindo Pharma Limited: Q4FY2021 Result Update - Weak quarter; Healthy outlook
  • Aurobindo Pharma Limited: Q4FY2021 Result Update

    1 Jun 2021 , 8:35AM Aurobindo Pharma Limited: Q4FY2021 Result Update - Weak quarter; Healthy outlook
  • Aurobindo Pharma Q4FY21: Weak Quarter

    31 May 2021 , 2:45PM Aurobindo Pharma Q4FY21: Weak Quarter; Adjusted PAT misses estimates
  • Aurobindo Pharma : Stock Update

    31 Mar 2021 , 12:09PM Aurobindo Pharma - Stock Update – A Potent dose
  • Aurobindo to begin COVID-19 vaccine production

    23 Mar 2021 , 2:08PM The company has invested Rs. 275 crore on the facility, which is expected to have a capacity to make 450 million doses.
  • Aurobindo, Sun Pharma

    15 Mar 2021 , 12:09PM As per media news, Aurobindo is recalling 1,296 bottles of Famotidine tablets, used to treat gastroesophageal reflux disease, in the US market for “presence of foreign tablets”. The recall is effective 20 January 2021 and the USFDA has classified this recall as class II, hence this is unlikely to have any material impact on the financials of the company. Sun Pharma is recalling Cequa ophthalmic solution, which is used to treat chronic dry eye. The company is recalling 37400 cartons of the medicine in the US markets for being impotent. The recall is effective 22 February 2021.
  • Aurobindo Pharma

    24 Feb 2021 , 11:24AM To invest Rs 5.32 crore each in NVNR (Ramanapet I and Ramannapet II) power plants Private Limited, which are engaged in the business of Solar power generation. Both the plants were incorporated in 2017 and are yet to start commercial operations. After the said investments the company would hold 26% stake in each of the power plants. This is Positive as the company would now be able to avail benefits of captive consumption of Solar Power.
  • Aurobindo Pharma acquires 26% stake each in 2 solar power firms

    24 Feb 2021 , 11:20AM Aurobindo Pharma inks pact to acquire 26% stake each in two Hyderabad-based solar power generating companies
  • Aurobindo Pharma

    22 Feb 2021 , 12:09PM As per media news, Hikima has alleges that Aurtobindo’s proposed generic version of gout treatment Mitigare infringes five patents. As per the USFDA, the patents for the said drug would expire in August 2033 and hence Hikma is seeking a court order blocking copies of the drug. The development is negative as it would delay the prospective product launch.
  • Aurobindo Pharma

    19 Feb 2021 , 12:12PM Aurobindo: Gets final approval from the USFDA for Droxidopa Capsules; 100 mg; 200 mg and 300 mg. The drug is indicated for the treatment of orthostatic dizziness and lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension. As per IQVIA the product approved has a market size of $352 mn for the most recent 12 months ending December 2020. The US constitutes around half of the overall sales of the company and given the sizeable market; the approval would be positive.
  • Aurobindo Pharma receives USFDA Approval for Droxidopa Capsules

    19 Feb 2021 , 12:09PM Droxidopa Capsules, used for the treatment of orthostatic dizziness & lightheadedness
  • Aurobindo Pharma

    15 Feb 2021 , 12:18PM As per media reports, the company is recalling affected lots of Acetaminophen injection from the US markets, due to discoloration and failed pH specifications. The affected lost was manufactured in India. The USFDA has classified the rcall as Class II recall which implies that use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Hence the recall is unlikely to have any material impact on the financial performance of the stock
  • Aurobindo Pharma: Q3FY2021 Result Update

    12 Feb 2021 , 10:53AM Aurobindo Pharma: Q3FY2021 Result Update – Growth Levers Intact
  • Aurobindo Pharma

    12 Feb 2021 , 9:36AM Aurobindo: Gets USFDA approval for injectable - Isoproternol Hydrochloride. The Injectable product is used to treat Asthma, Bronchitis and emphysema and Aurobindo is the 6th player to get the approval. The approval is positive as it would add to the US sales, which is around half of the company’s overall sales.
  • Aurobindo Pharma Q3FY21

    11 Feb 2021 , 10:18AM Aurobindo Pharma Q3FY21: Strong performance; Adjusted PAT marginally misses estimates
  • Aurobindo Pharma

    25 Jan 2021 , 2:24PM Aurobindo Pharma: Gets approval from the Government of India under the PLI scheme for promotion of domestic manufacturing of critical bulk drugs. Aurobindo has got approval through Lyfius Pharma for production of Penicillin G, and 7-ACA, with committed production capacity of15,000 MT and2,000 MT, respectively with a committed investment for Penicillin G at Rs 1392 crore and Rs 813 crore for 7-ACA, Also Aurobindo Pharma has received approval through Qule Pharma for setting up plant for production of Erythromycin Thiocyanate with a capacity of 1600 MT at a committed investments of Rs 834 crore. The collective investments stand at Rs 1303 crore. As India is dependent fully on imports for all the three products - Penicillin G,7-ACA and Erythromycin Thiocyanate would make India self reliant for these products and also would open up a new growth avenue for Aurobindo, hence positive.
  • Aurobindo Pharma

    15 Jan 2021 , 10:21AM Pfizer has sued Aurobindo in the US court of Delaware to block copies of Xeljanz Arthritis Drug. Pfizer has said that Aurobindo’s proposed generic versions of an arthritis drug’s 5-milligram and 10-milligram tablets infringe two patents for Pfizer’s blockbuster Xeljanz, which expire in March 2023 and December 2025. Pfizer is seeking an injunction against Aurobindo, stopping it from producing the generic versions, or compensation if the company succeeds in bringing its generic version. If Pfizer gets an injunction, this is negative for Aurobindo.
  • Aurobindo Pharma inks pact with Covvax for COVID vaccine

    24 Dec 2020 , 1:32PM News positive for Aurobindo if Covaxx vaccine clears trials successfully and is approved by regulators.
  • Aurobindo Pharma Limited: Stock Update

    18 Dec 2020 , 12:07PM Aurobindo Pharma: Stock Update - Taking off on the growth runway
  • Aurobindo Pharma

    10 Dec 2020 , 11:09AM Aurobindo Pharma: gets approval from the USFDA for Cyanocobalamin. The drug is to treat lack of vitamin B12 caused due to pernicious anemia. The product approval is positive as it would add to the US sales of the company, which constitute almost half of the Overall revenues.
  • Aurobindo Pharma

    9 Dec 2020 , 12:59PM Aurobindo: gets USFDA approval for t Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, 200 µg/50 mL and 400 µg/100 mL Single Dose flexible containers (Bags), which is a a therapeutic equivalent generic version of Precedex. The injection is indicated for a) sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting; b) sedation of non-intubated patients prior to and/or during surgical and other procedures. Aurobindo would be launching the product in January 2021. As per IQVIA, the approved product has a market size of $ 228 mn as of 12 months ending October 2020. The approval and the launch of the product would be positive as it would help growth the US sales, which are around half of the overall revenues
  • Aurobindo Pharma receives USFDA nod for Dexmedetomidine HCL

    9 Dec 2020 , 10:58AM Aurobindo Pharma gets USFDA nod for sedative dexmedetomidine injection
  • Aurobindo Pharma

    8 Dec 2020 , 10:34AM As per media reports, Aurobindo has received USFDA approval for Ketorolac Tromethamine Opthamlmic drops (0.5%), a painkiller. The medicine is used to treat itchy eyes caused by allergies. It also is used to treat swelling and redness (inflammation) that can occur after cataract surgery. The approval is positive as it would add to the US business growth.
  • Aurobindo Pharma

    18 Nov 2020 , 11:15AM Gets USFDA Approval for Phenylephrine Hydrochloride. The drug is used to relieve nasal discomfort caused by colds and allergies. US constitute almost half of the overall sales of the company and the approval is positive as it would add to the overall revenues.
  • Aurobindo Pharma Q2FY21

    12 Nov 2020 , 10:05AM Aurobindo Pharma Q2FY21: Strong quarter; Results in line with estimates on the operating front
  • Aurobindo Pharma

    30 Oct 2020 , 10:13AM Aurobindo Pharma: Has received an approval from USFDA for Cisatracurium Besylate,. The drug is used to maintain neuromuscular relaxation during major surgical procedures. The approval is positive as it would help add to the US business growth.
  • Aurobindo Pharma

    30 Oct 2020 , 9:02AM Aurobindo Pharma gets US FDA nod for Cisatracurium Besylate, used to maintain neuromuscular relaxation during major surgical procedures
  • Aurobindo Pharma

    27 Oct 2020 , 11:13AM As per media news, Novartis has filed a complaint in the US Federal Court in Delaware against the company, stating that Aurobindo's proposed generic version of a treatment for dry eye infringes 15 patents for Novartis’s Xiidra. Novartis has sought a court order blocking copies until the patients expire. The court on this would be awaited.
  • Aurobindo Pharma to divest Natrol to New Mountain Capital

    26 Oct 2020 , 12:09PM Aurobindo inks pact with New Mountain Capital to sell US-based unit for $550 million
  • Aurobindo Pharma

    26 Oct 2020 , 10:04AM Aurobindo has reached a definitive agreement with New Mountain Capital and its affiliate Jarrow Formulas for the divesture of business assets of Natrol LLC., a wholly owned subsidiary of Aurobindo Pharma USA. The all-cash transaction is valued at $550 Million (translating to around Rs 4048 Cr). The deal is subject to customary closing conditions and regulatory approvals and is expected to close by January 2021.
  • Aurobindo Pharma receives USFDA approval for Acetaminophen Injection

    22 Oct 2020 , 12:20PM USFDA approval for Acetaminophen Injection
  • Aurobindo Pharma

    22 Oct 2020 , 10:22AM The company’s wholly owned, step down subsidiary – Auro Life Pharma LLC has received a Warning Letter from the USFDA for its oral solids manufacturing facility based in New Jersey (USA). The facility was earlier classified as an OAI (Official Action Indicated) in June 2020. The management believes that the existing business from the facility would not be impacted. However, following the warning Letter the new product approval from the plant could be held back and could slow down the revenue growth going ahead.
  • Aurobindo arm gets warning letter from USFDA

    22 Oct 2020 , 10:06AM Aurobindo arm AuroLife Pharma gets warning letter from USFDA for New Jersey unit
  • Aurobindo Pharma

    19 Oct 2020 , 9:55AM Aurobindo: to acquire a 100% stake in MViyes Pharma to gain a 100% stake in Eugia Pharma, present in the generic oncology formulations; product portfolio to complement Aurobindo’s existing portfolio and open up new growth avenues - positive
  • Aurobindo Pharma: Stock update

    23 Sep 2020 , 11:29AM Aurobindo Pharma: Stock update – Promising Outlook; Upgrade to Buy
  • Aurobindo Pharma tie up with CSIR for Covid vaccines

    16 Sep 2020 , 11:51AM CSIR, Aurobindo Pharma collaborate to develop COVID-19 vaccine
  • Aurobindo Pharma

    16 Sep 2020 , 9:13AM Collaborates with Council of Scientific and Industrial Research to develop Covid 19 Vaccine; is also developing its own vaccine through subsidiary company – Auro Vaccines: Given the increasing Covid cases the development is positive if the vaccine is approved.
  • Aurobindo Pharma

    8 Sep 2020 , 10:14AM Gets USFDA approval nod for cardiac arrest drug – Milrinone Lactate. The drug is used for short-term treatment of heart failure. The approval is positive as it it would add to the US business growth. Also The board of directors have approved a scheme of amalgamation of five of its wholly owned subsidiaries with itself. The amalgamation would result in efficient utilization of their resources, greater economies of scale, reduction in overheads and other expenses and improvement in various operating parameters.
  • Aurobindo Pharma

    7 Sep 2020 , 12:08PM As per media news, the promoters have created a pledge on 67 lakh shares of the company. With this the proportion of the pledge shares to increase to 8.3% from earlier levels of 6.2%.
  • Aurobindo Pharma

    14 Aug 2020 , 11:49AM Aurobindo Pharma: Q1FY21 Result Update – Mixed Quarter
  • Aurobindo Pharma

    14 Aug 2020 , 9:56AM Gets USFDA approval for ANDA methocarbamol. The drug is used to treat Muscle spasms. The approval is positive as it could add to the US business growth.
  • Aurobindo Pharma

    13 Aug 2020 , 10:28AM Aurobindo Pharma Q1FY21: healthy quarter; PAT ahead of estimates due to low interest, high other income
  • Aurobindo Pharma

    14 Jul 2020 , 9:17AM Gets USFDA approval for Albuterol Sulfate & Ipratropium Bromide solution. The combination drug is used to treat chronic obstructive pulmonary disease. The approval is positive as this would help improve the US business.
  • Aurobindo Pharma

    10 Jul 2020 , 9:51AM Gets US FDA approval for Chlorpromazine Hydrochloride injection which is used to reduce psychotic symptoms like hallucinations & delusions. The drug is also used to treat Schizophrenia. The approval is positive as it could help improve the US business, which is almost half of sales.
  • Aurobindo Pharma

    9 Jul 2020 , 9:19AM Gets USFDA approval for Verapamil Hydrochloride. The drug is used for treatment of high blood pressure and may also be used for the prevention of migraines and cluster headaches. The approval is positive as it could help improve the US business, which is almost half of sales.
  • Lupin, Aurobindo Pharma, Alembic Pharmaceuticals

    6 Jul 2020 , 11:41AM Indian drug firms like Lupin, Marksans Pharma, Aurobindo Pharma and Alembic Pharmaceuticals are recalling products in the US market, as per the latest enforcement report by the USFDA. While Lupin and Marksans Pharma are recalling diabetes drug, Aurobindo and Alembic are recalling psychiatric medication in the US market. Aurobindo is recalling 1,440 bottles of Clozapine tablets in the US market. The drug is used to treat certain mood /mental disorders. All the recalls have been classII recalls and hence unlikely to have any material impact on the earnings of the company. Sentimentally Negative
  • Aurobindo Pharma

    23 Jun 2020 , 12:13PM As per media reports, the Board has approved closure of operations at the Daman manufacturing facility, which is a Betalactum block. The facility contributed 0.8% of the total turnover and mainly catered to the international market and was significantly under-utilized. Given the insignificant contribution to the revenues, the closure is unlikely to have any material impact on the performance.
  • Aurobindo Pharma

    16 Jun 2020 , 10:10AM As per media reports, the company gets USFDA approval Fluoxetine Hydrochloride tablets. The medicine is indicated to treat depressive disorder, obsessive-compulsive disorder, panic disorder. The approval would be positive as this would enable improvement in the US business, which is almost half the total sales.
  • Aurobindo Pharma

    11 Jun 2020 , 10:07AM As per media news the company gets USFDA approval for dexamethasone sodium phosphate. The drug is used specifically to decrease swelling (edema), associated with tumors of the spine and brain, and to treat eye inflammation. This is positive as the approval would help improve the company’s US business, which accounts for half of the sales.
  • Aurobindo Pharma

    5 Jun 2020 , 10:20AM Revenue rises strongly by 16.4% y-o-y, on a high base of the corresponding quarter.
  • Aurobindo Pharma

    4 Jun 2020 , 11:04AM Aurobindo Pharma Q4FY2020: Operationally strong result; PAT ahead of estimates
  • Aurobindo Pharma

    4 Jun 2020 , 10:20AM The company reported better than estimated results for Q4FY2020. Sales grew by 16.4% aided by a strong growth in formulations across geographies. OPM’s expanded by 180 bps to 21.8% (ahead of the estimated 20.7%) aided by an expansion in gross margins due to better product mix. The adjusted PAT stood at Rs 882 cr, up sturdily by 41% YoY and was ahead of estimates. Positive read thru
  • Aurobindo Pharma

    19 May 2020 , 9:51AM As per media news the company gets USFDA approval for Albuterol Sulfate. The drug is used to treat wheezing & shortness of breath. Positive as this would drive the performance of the US business which constitutes almost half of the revenues.
  • Aurobindo Pharma

    15 May 2020 , 10:42AM The SEBI has passed an Adjudicating order against the company and the promoters dated 23 September 2019 for alleged violations of the SEBI regulations. Post that the company had filed for a settlement order, which was accepted by SEBI dated 6 May 2020. Consequently, the company and the promoters have paid settlement charge of Rs 2.2 cr and Rs 19.81 cr. Consequently, pending enforcement proceedings stand settled qua the Company and its promoters and no enforcement action will be initiated by SEBI in respect of the aforesaid allegations.
  • Aurobindo Pharma

    14 May 2020 , 2:36PM As per media news, Teva has filed an patent infringement suit in the US against Aurobindo Pharma and has seeked a ban on the generic version of Bendeka sold by Aurobindo. Teva holds the patent for Bendeka, a drug used to treat cancer. Further details on this are awaited. Sentimentally Negative for Aurobindo, however, this is a usual practice in the Pharma space and we don’t see any major impact of the same.
  • Aurobindo Pharma

    13 May 2020 , 9:12AM As per media reports the Company gets US FDA nod for Ibuprofen tablets & Azelastine Hydrochloride nasal spray. Positive as this could aid the improvement in the US business.
  • Aurobindo Pharma

    6 May 2020 , 5:56PM As per media reports, the USFDA has classified the company’s unit 10 and 12 as VAI. Positive as this would now enable the company to improve its US business which constitutes around half the revenues.
  • Aurobindo Pharma

    4 May 2020 , 12:17PM Gets final approval from USFDA for Flucytosine Capsules, 250 mg and 500 mg. This is a generic version of Ancobon capsules. The product would be launched in June 2020. Flucytosine Capsules are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus. The drug has a market size of $43 mn as of 12 month ending March 2020 as per IQVIA. The launch could lead to improvement in Aurobindo’s US business.
  • Aurobindo Pharma receives USFDA approval for Flucytosine Capsules

    4 May 2020 , 12:07PM USFDA approval for Flucytosine Capsules
  • Aurobindo

    24 Apr 2020 , 9:42AM As per media news, gets approval for Albuterol Inhalation Solution which is likely to be manufactured from unit 4. The unit 4 has recently been classified as VAI (Voluntary Action Indicated) by the USFDA. The Drug is a generic version of Accuneb with a sub-100 mn market. Positive
  • Aurobindo Pharma

    23 Apr 2020 , 9:48AM The company has received a USFDA approval for Pantoprazole Sodium Injectables with strength of 40 mg. The drug is used to treat various abdominal issues. This would further improve the US business. Positive
  • Aurobindo Pharma

    21 Apr 2020 , 11:45AM The USFDA has classified the Unit IV as VAI (Voluntary Action Inidcated). Unit IV is a general injectable formulation manufacturing facility and had got a rescindment of 90 days and was under review of the regulator as per announcement dated 21st Feb 2020. The VAI status indicates a closure of the inspection. Positive as the company had significant number of products filed from this facility
  • Aurobindo Pharma up as FDA's VAI status for Hyderabad unit

    21 Apr 2020 , 11:07AM Aurobindo Pharma rises over 16% to Rs. 628, after company's Unit-IV is classified as Voluntary Action Indicated by USFDA
  • Aurobindo Pharma

    9 Apr 2020 , 2:19PM The company has received a final approval for the USFDA for Fluoxetine Tablets, 10 mg and 20 mg. Fluoxetine tablets are generic version of Eli Lilly’s Prozac tablets. Drug is indicated for the acute and maintenance treatment of major depressive disorder in adult patients and in pediatric patients, obsessions and compulsions with obsessive compulsive disorder (OCD), and treatment of binge-eating and vomiting behaviours in adult patients. The product launch would be in April 2020 and as per IQVIA the approved products have an estimated market size of USD 42 mn for 12 months ending February 2020. The new product launch would widen the company’s US product offerings and could aide revenue growth.
  • Aurobindo Pharma receives USFDA approval for Fluoxetine Tablets

    9 Apr 2020 , 12:52PM Aurobindo Pharma gets USFDA nod for fluoxetine tablets, will launch in April 2020
  • Aurobindo Pharma

    8 Apr 2020 , 9:37AM As per media reports, A class action suit has been filed against Aurobindo Pharma in a U.S. court for allegedly concealing facts about a cancer-causing agent, N- nitrosodimethylamine presence in metformin medicine, which is used to treat type 2 diabetes patents. The is likely to impact the supplies of the drug in the US. Negative
  • Aurobindo Pharma

    3 Apr 2020 , 10:01AM Announced mutual termination of its agreement with Sandoz Inc (US) to acquire US generic business of oral solids and Dermatology, as approval from the US Federal trade commission was not obtained within anticipated time line – Negative as US business growth potential could be impacted
  • Aurobindo Pharma

    27 Mar 2020 , 11:36AM As per media news Aurobindo Pharma gets an USFDA approval for Muscle Relaxant - Tizanidine Hydrochloride. This is positive as it would widen the company’s offerings in US markets
  • Aurobindo gets EIR for Hyderabad facility from USFDA

    27 Mar 2020 , 9:45AM Receives an EIR from the US drug regulator
  • Aurobindo's Hyderabad unit gets EIR from USFDA

    26 Feb 2020 , 10:15AM Aurobindo Pharma gets EIR for Unit VIII of Gaddapotharam API facility with VAI status from USFDA
  • Aurobindo pharma

    24 Feb 2020 , 10:50AM The USFDA has revoked the VAI (Voluntary Action Indicated) status for the company’s Unit 4 (general injectable formulation facility). The plant was inspected in between 4th November 2019 to 13th November 2019. The USFDA has stated that the inspection is still open and under review. Thus the overhang of the unit 4 being classified as a OAI (official action indicated) or a Warning Letter stays. Following the VAI status indicated earlier, the stock had surged ~20% and with this recent development, the stock is likely to give up these gains. Negative
  • Aurobindo Pharma

    20 Feb 2020 , 10:57AM As per media news the company has received an approval from the USFDA for Montelukast Sodium. The drug is indicated for treating Asthma and seasonal allergic rhinitis or hay fever. Positive as this would strengthen the company’s presence in the US markets
  • Aurobindo Pharma

    19 Feb 2020 , 10:25AM As per media news, Aurobindo Pharma’s unit 4 has been classified as Voluntary Action initiated (VAI) by USFDA. This facility had 14 observations and was widely expected to receive and adverse classification from USFDA. This is a positive development for Aurobindo Pharma.
  • Aurobindo Pharma gets EIR from USFDA

    19 Feb 2020 , 10:15AM Aurobindo Pharma receives establishment inspection report (EIR) from USFDA
  • Aurobindo Pharma

    13 Feb 2020 , 11:55AM Auro Vaccines LLC, a step down subsidiary company has completed the acquisition of Profectus biosciences Inc, a clinical-stage vaccine development company. The Effective date for completion of the acquisition is 11 Feb 2020. This acquisition would enable Aurobindo Pharma to develop certain assets for commercialization and also provide access to Proprietary & innovative technology platforms for Prohylactic use and Therapeutic use. This would help Aurobindo to widen its offerings in the US. Positive read thru
  • Aurobindo Pharma

    10 Feb 2020 , 1:06PM Aurobindo Pharma: Q3FY2020 result update
  • Aurobindo Pharma

    7 Feb 2020 , 11:35AM Aurobindo Pharma: results largely in line with estimates operationally
  • Aurobindo Pharma

    31 Jan 2020 , 11:29AM As per media news, After Official Action Indicated to Aurobindo's Unit 7 - all eyes are on Unit 4, which is the injectables Unit and was issued 14 observations in November 2019. If unit 4 also gets an OAI as in the case of unit 7, then it would have an adverse impact on the performance. Collectively, both the units (unit 7 and 4) account of over 40% of pending new approvals for the US. In addition to this company’s Unit 11 is under “Warning Letter” and Unit
  • Aurobindo Pharma

    30 Jan 2020 , 11:37AM The USFDA has classified company’s unit VII, an oral solids formulation facility as OAI (Official Action Indicated). The plant was inspected between October 7-11, 2019. The Company believes that this OAI classification will not have any material impact on the existing revenues or supplies to US at this juncture, however approvals for new products could be with-held and this could have an adverse impact on company’s performance. Negative.
  • Aurobindo unit VII gets OAI from USFDA

    30 Jan 2020 , 10:46AM USFDA classifies the inspection of Company's unit-VII facility as OAI
  • Aurobindo Pharma

    28 Jan 2020 , 11:32AM As per media news the promoters released pledge on 2 lakh shares on 23 January 2020. As of quarter ending December 2019, 4.99% shares (1.51 cr shares) of total held were pledged. Release of 2 lakh shares is very low and is unlikely to have any material impact on the stock.
  • Aurobindo Pharma

    9 Dec 2019 , 2:38PM Aurobindo Pharma: As per media news, company initiates recall of three drugs from US market; negative read thru
  • Aurobindo arm to buy certain biz assets of Profectus BioSciences

    29 Nov 2019 , 10:45AM Aurobindo Pharma subsidiary enters in pact with Profectus BioSciences to buy certain business assets
  • Aurobindo Pharma Ltd

    21 Nov 2019 , 11:29AM As per media news, The USFDA inspected Aurobindo’s plant V and VIII in October 2019 and has sent 4 observations each for the respective plants: Negative read thru
  • Aurobindo Pharma

    14 Nov 2019 , 11:38AM Aurobindo Pharma: Q2FY20 Stock Update - Regulatory overhang persists
  • Aurobindo Pharma

    14 Nov 2019 , 10:51AM The USFDA has completed the inspection of unit IV plant (inspected between 4-13 November 2019) which is a general injectable formulations manufacturing plant at Pashamylaram (Hyderabad). The USFDA has issued a form 483 with 14 observations. The company has around 47 pending fillings (~30% of overall filings) related to the plant. The management has stated that, there were no data integrity issues in the 14 observations, however we believe the development will continues to weigh on the stock performance, till the time clarity emrge. We have a HOLD rating on the stock.
  • Aurobindo Pharma

    13 Nov 2019 , 11:07AM Aurobindo Pharma Q2FY20: In line performance
  • Aurobindo Pharma

    18 Oct 2019 , 11:19AM Aurobindo Pharma: As per media news the company gets US FDA nod for Naloxone Hydrochloride injection. The Naloxone injection is used to treat a narcotic overdose in an emergency situation. Positive
  • Aurobindo Pharma

    9 Oct 2019 , 11:10AM Aurobindo: Management of Aurobindo has clarified that none of the observations issued by the USFDA for Unit-VII were related to data integrity and it is confident of addressing them within the stipulated timeline – Sentimentally positive; Unit- VII is one of the important facilities in terms of future filings and contribution to US business (~15% sales). Stocks corrected close to 18-19% in trade on Monday.
  • SEBI slaps Rs. 22 crore penalty on Aurobindo Pharma

    24 Sep 2019 , 11:10AM Aurobindo Pharma rises by 4% to Rs. 589.5, after SEBI imposes a penalty on the company's promoter
  • SEBI imposes fine on Aurobindo’s promoter

    24 Sep 2019 , 10:55AM Aurobindo: SEBI imposes Rs 22 crore fine on Aurobindo’s promoter, Mr. PV Ramaprasad Reddy and other connected entities, for violating insider trading norms –Negative read thru.
  • Aurobindo Pharma gets USFDA nod

    23 Aug 2019 , 12:34PM Aurobindo Pharma: Company gets USFDA nod for anti-bacterial antibiotic, Minocycline Hydrochloride tablets - Positive.
  • Aurobindo launches Cinacalcet Hydrochloride tablets in US

    11 Jul 2019 , 11:46AM Aurobindo: Company to launch Cinacalcet Hydrochloride (gSensipar) Tablets in the US – Positive read-thru
  • Aurobindo launches Cinacalcet Hydrochloride tablets in US

    11 Jul 2019 , 11:46AM Aurobindo: Company to launch Cinacalcet Hydrochloride (gSensipar) Tablets in the US – Positive read-thru
  • Aurobindo introduces Cinacalcet Hydrochloride Tablets in US

    11 Jul 2019 , 10:47AM Launch of Cinacalcet Hydrochloride Tablets in USA
  • Aurobindo Pharma gets warning letter from USFDA for Andhra Pradesh unit

    21 Jun 2019 , 12:03PM Drug firm gets warning letter following inspection in February
  • Aurobindo Pharma gets warning letter from USFDA for Andhra Pradesh unit

    21 Jun 2019 , 12:03PM Drug firm gets warning letter following inspection in Feburary
  • Aurobindo management clarifies, No data integrity issue for Bachupally (Unit – III)

    14 Jun 2019 , 1:34PM We had a short discussion with the Aurobindo’s management today to get more clarity on Form 483 received for Bachupally (Unit – III). Management clarifies that there are no data integrity lapses at Bachupally (Unit – III) which has received Form 483 with 10 observations (audited during May 13 and May 24, 2019). They further clarified that, the particular observation related to incomplete data filing/missing data (due to failure of process completion) points toward failure of following the procedures – Although clarification comes as a breather (as operations/financials are not impacted currently), we feel final outcome of audit will continue to weigh on stock performance in near to medium term.
  • Aurobindo Pharma falls in weak market

    14 Jun 2019 , 12:18PM Aurobindo Pharma dips by 5% in the weak market
  • Aurobindo gets USFDA nod to treat bacterial infections

    14 Jun 2019 , 10:45AM Aurobindo : Company gets USFDA approval for Tigecycline injectable (antibiotic to treat bacterial infections) - Positive
  • Aurobindo receives Form 483 with 10 observations from USFDA

    6 Jun 2019 , 10:52AM Aurobindo: Company received Form 483 with 10 observations from USFDA for formulation facility (Unit – 3) in Hyderabad (inspected between 13th May to 24th May 2019). Company stated that these observations are repetitive and procedural in nature and Form 483 will not have an impact on existing business – Negative overhang until final outcome.
  • Aurobindo stock to remain in focus

    4 Jun 2019 , 11:05AM Aurobindo: Generic drug distributor Aceto (in its bankruptcy filing) accuses Aurobindo of fraud, negligent misrepresentation and sabotaging its business so Aurobindo could later compete for its customers – Negative overhang; stock to remain in focus until matter is resolved.
  • Aurobindo Q4FY2019 profit below estimate

    29 May 2019 , 10:59AM Aurobindo Q4FY2019 profit below estimate due to high tax rate
  • USFDA classifies inspection as OAI

    17 May 2019 , 11:04AM Aurobindo Pharma – Company has received communication from the USFDA classifying API facilities of Unit I and XI and intermediates facility of unit IX inspected in February 2019 as Official Action Indicated (OAI) – Negative; OAI classifications will not have an impact on disruption of supplies or the revenue from operations of these facilities but the final outcome will weigh on stock in near to medium term.
  • Aurobindo falls as USFDA classifies inspection

    17 May 2019 , 10:13AM USFDA classifies the inspection of Aurobindo's API/ Intermediates Facilities of Unit I, IX And XI As OAI
  • Aurobindo Unit 16 manufacturing sterile drugs gets 11 observations from US FDA

    13 Mar 2019 , 11:26AM Aurobindo: Company’s Unit 16 manufacturing sterile drugs gets 11 observations from US FDA – Negative, await management clarification. One of those observations indicates appropriate controls were not exercised over computers or related systems to assure that changes are instituted only by authorised personnel.
  • Aurobindo Pharma 3 API units underwent USFDA inspection

    13 Feb 2019 , 11:48AM Aurobindo: Aurobindo Pharma’s 3 API units (Unit 1,9 & 11) underwent USFDA inspection (management had indicated on Q3FY2019 earnings call that sites where Valsartan API’s are manufactured, are undergoing re-inspection); As per media reports, Unit 1 & 9 received six observations each whereas Unit – 11 received 3 observations – Sentimentally Negative; Await management clarification.
  • Aurobindo Q3FY2019

    8 Feb 2019 , 11:19AM Aurobindo Q3FY2019: Operating performance below expectation
  • Aurobindo to buy oncology drugs from US company

    18 Jan 2019 , 11:23AM Subsidiary Acrotech Biopharma LLC to buy 7 oncology drugs from US company Spectrum Pharma
  • Aurobindo to acquire to buy oncology drugs from US company

    18 Jan 2019 , 11:22AM Subsidiary Acrotech Biopharma LLC to buy 7 oncology drugs from US company Spectrum Pharma
  • Aurobindo gets USFDA nod for Vecuronium Bromide Injection

    24 Dec 2018 , 12:27PM Aurobindo Pharma receives USFDA approval for Vecuronium Bromide Injection, to be launched in Q4FY19
  • Aurobindo Pharma gets USFDA nod for Potassium Chloride ER Tablets

    21 Dec 2018 , 1:04PM Aurobindo Pharma receives USFDA approval for generic of Klor-con extended release tablets
  • Aurobindo gets USFDA tentative nod for combination drug

    19 Nov 2018 , 1:05PM Aurobindo Pharma receives USFDA tentative nod for combination drug - abacavir sulfate and lamivudine
  • Aurobindo gets drug approval from USFDA

    11 Oct 2018 , 12:20PM Aurobindo Pharma receives USFDA Approval for Azithromycin Oral Suspension
  • Aurobindo gets South Africa nod for HIV drugs

    18 Sep 2018 , 10:50AM Local regulator SAHPRA approves sale of three tablets
  • Aurobindo buys dermatology and oral solids biz from Sandoz

    6 Sep 2018 , 11:32AM Aurobindo Pharma acquires dermatology and oral solids businesses from Sandoz Inc., USA for upfront purchase price of $0.9 billion (~Rs 6400 crore) in cash, which Aurobindo will finance through debt – Positive for Aurobindo; Transaction is expected to be accretive to normalized EPS from first full year of ownership; D:E as on FY2018 stands at 0.4x.
  • Aurobindo to acquire certain assets from Sandoz US

    6 Sep 2018 , 10:09AM Aurobindo Pharma rise over 4% to Rs727.9, after company announces the signing of a definitive agreement to acquire certain assets from Sandoz Inc., US
  • Aurobindo reports profit below expectation

    10 Aug 2018 , 11:29AM Aurobindo Q1 net profit falls 12% to Rs455.6 cr for the Quarter ended June 30, 2018
  • Aurobindo gets USFDA nod for Bivalirudin Injection

    30 Jul 2018 , 2:04PM Aurobindo Pharma receives USFDA approval for Bivalirudin injection (gAngiomax), used as an anticoagulant
  • Aurobindo Pharma to acquire Apotex International Inc

    16 Jul 2018 , 10:53AM Aurobindo Pharma signs definitive agreement to acquire Apotex' businesses in Poland, Czech Republic, Netherlands, Spain & Belgium for 70 million euro
  • Aurobindo company gets USFDA approval

    27 Jun 2018 , 2:54PM Positive read through for Aurobindo Pharma.
  • Aurobindo Company gets USFDA approval for Ertapenem Injection

    26 Jun 2018 , 2:46PM Positive read through for Aurobindo.
  • Aurobindo gets USFDA nod for heartburn drug; stk up

    8 Jun 2018 , 11:54AM Aurobindo Pharma rises over 3% at Rs566.7, after receiving USFDA approval for heartburn drug
  • Aurobindo Pharma reports weak quarter and improved outlook

    30 May 2018 , 11:33AM We maintain our Buy recommendation with an unchanged price target (PT) of Rs. 725.
  • Aurobindo launches $1.6 billion bid to buy Novartis generics unit

    7 May 2018 , 10:59AM Stock to remain in focus as Aurobindo launches $1.6 billion bid to buy Novartis generics unit.
  • Aurobindo gets USFDA approval for Emtricitabine capsules

    27 Mar 2018 , 9:10AM Positive for Aurobindo as the company gets USFDA approval for Emtricitabine capsules.
  • Aurobindo gets three observations for its Auronext facility

    16 Mar 2018 , 12:12PM Stock to remain in focus as Aurobindo gets three observations for its Auronext facility (a penem plant in Rajasthan).
  • Aurobindo gets USFDA approval for HIV drug

    16 Mar 2018 , 9:47AM Positive read through for Aurobindo Pharma as it gets USFDA approval for HIV drug, Abacavir Sulfate Solution.
  • No critical observations reported in Form 483 for Aurobindo Pharma

    6 Mar 2018 , 9:33AM We maintain our Buy recommendation on the stock with unchanged price target (PT) of Rs. 725 (valuing the stock at 12x its FY2019E earnings).
  • Aurobindo Pharma received Form 483 from the USFDA

    5 Mar 2018 , 9:21AM Negative read through for Aurobindo Pharma as it received Form 483 from the USFDA for its Unit IV with nine observations (no data integrity issues).
  • Aurobindo Pharma currently undergoing USFDA inspection

    20 Feb 2018 , 2:12PM Stock to remain in focus as Aurobindo Pharma undergoes USFDA inspection
  • Aurobindo Pharma reports Q3FY18 results in-line with estimates

    8 Feb 2018 , 2:40PM We currently have buy recommendation on the stock.
  • Aurobindo Pharma gets USFDA nod

    29 Dec 2017 , 9:30AM Positive read through for Aurobindo Pharma as it gets USFDA nod for Fondaparinux Sodium injection.
  • Aurobindo Pharma get USFDA nod for anti-anxiety drug

    28 Dec 2017 , 9:42AM Positive read-through as the company Aurolife pharma LLC get USFDA nod for anti-Anxiety drug , Lorazepam (0.5-2 mg) tablet
  • Aurobindo Pharma issued a nationwide recall of Pantoprazole sodium

    21 Dec 2017 , 9:58AM Negative read through for Aurobindo taking into consideration this negative development which could lead to regulatory issues in future.
  • Aurobindo Pharma

    19 Dec 2017 , 9:45AM Aurobindo Pharma gets a tentative nod from USFDA
  • Aurobindo Pharma gets USFDA nod for Ranolazine

    6 Dec 2017 , 2:26PM Aurobindo Pharma gets U.S.FDA approval for Ranolazine Extended Release Oral Tablet
  • Aurobindo Pharma gets USFDA nod for Ranolazine Extended Release Oral Tablet

    6 Dec 2017 , 9:06AM Sentimentally Positive for Aurobindo Pharma ; no material change in estimates
  • Aurobindo’s Unit 10 clears USFDA inspection

    28 Nov 2017 , 8:57AM Positive for Aurobindo; Aurobindo continues to be one of our preferred pick.
  • Aurobindo Pharma's Q2 operational performance driven by strong growth

    13 Nov 2017 , 12:16PM Aurobindo Pharma: Strong Q2; commentary cautious Maintain buy.
  • Aurobindo reports strong operational quarter

    10 Nov 2017 , 3:28PM Aurobindo Pharma's sales for the quarter grew by 17.5% to Rs 4436 crore.
  • Aurobindo gets USFDA nod for drugs used to treat allergy symptoms

    2 Nov 2017 , 9:56AM Positive news for Aurobindo as USFDA gives approval for fexofenadine (used to treat allergy symptoms such as hay fever; market size of ~ Rs 1500 crore ) & Pseudoephedine Hydrochloride tablets (used as nasal decongestant)
  • Aurobindo gets USFDA approval for two drugs - positive

    23 Oct 2017 , 8:59AM Aurobindo gets USFDA approval for two drugs, namely 1) Albuterol Sulfate (used to treat wheezing and shortness of breath caused by breathing problems such as asthma) and 2) Fluphenazine Decanoate (used to treat certain mental/mood problems like chronic schizophrenia) – Positive for Aurobindo
  • Aurobindo: Stock update - New product launches to help mitigate pricing pressure in the U.S

    18 Oct 2017 , 9:44AM Aurobindo Pharma (Aurobindo) has received USFDA approval for gNexium 24HR over the counter (OTC) oral capsule. Nexium 24HR capsule is one of the biggest-selling OTC treatments for frequent heartburn, with annual sales estimated at more than $300 million, i.e. ~Rs.1,950 crore.
  • Aurobindo pharma gets USFDA approval for gNexium 24hr OTC capsule – Positive

    17 Oct 2017 , 11:14AM Aurobindo pharma gets USFDA approval for gNexium 24HR over the counter (OTC) capsule – Positive for Aurobindo.
  • Auro Pharma gets USFDA nod for Metronidazole

    11 Sep 2017 , 12:14PM Aurobindo Pharma gets USFDA approval for pelvic inflammatory drug Metronidazole tablet – Positive for Aurobindo.
  • Aurobindo Pharma completes USFDA inspections successfully

    4 Sep 2017 , 10:09AM As per media reports, Unit 6 of Aurobindo gets 2 observations from USFDA, while the Eugia site (oncology and hormones plant) cleared without observations – positive for Aurobindo
  • Aurobindo Pharma gets USFDA approval for HIV treatment tablets

    21 Aug 2017 , 11:10AM This news is sentimentally positive for Aurobindo, which last traded at 704.75
  • Aurobindo Pharma in race with Intas Pharma

    16 Aug 2017 , 9:18AM Aurobindo Pharma is in race with Intas Pharma to acquire assets of Teva Pharma – Israeli generic drug maker.
  • Aurobindo: Outlook positive

    11 Aug 2017 , 8:57AM Aurobindo Pharma (Aurobindo) reported lower-than-expected results for Q1FY20185
  • Aurobindo: Q1FY2018 numbers below expectation

    10 Aug 2017 , 10:45AM Aurobindo Pharma Q1 FY2018 Sales slips by 2.3% to Rs3679 crore
  • Aurobindo in race to buy Mallinckrodt's generic drugs business in the US

    9 Aug 2017 , 8:53AM As per media reports, Aurobindo pharma and Intas are in race to buy Mallinckrodt's generic drugs business in the US – positive read thru.
  • Aurobindo gets FDA nod for tablet version gRenvela

    19 Jul 2017 , 10:14AM Aurobindo Pharma surges over 8% to Rs794.5, after receiving final approval from the US drug regulator to manufacture Sevelamer Carbonate tablets 800mg

Key fundamentals

Evaluate the intrinsic value of Aurobindo Pharma Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 22540.66 22056.74 18935.96 19877.71 16755.88
Liabilities 22540.66 22056.74 18935.96 19877.71 16755.88
Equity 58.59 58.59 58.59 58.59 58.59
Gross Profit 2224.04 1730.92 1473.4 4119.83 2685.75
Net Profit 1954.14 1230.41 1454.71 3112.91 1872.74
Cash From Operating Activities 1714.8 1821.16 3726.71 2994.41 2161.73
NPM(%) 18.35 9.61 12.88 19.67 14.11
Revenue 10645.64 12792.28 11287.14 15823.68 13266.48
Expenses 8421.6 11061.36 9813.74 11703.85 10580.73
ROE(%) 6.32 3.98 4.71 10.08 6.06

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
20 Feb 2024 1.5 150 0.41 994.25
20 Nov 2023 3 300 0.41 855.95
17 Feb 2023 3 300 0.41 404.2
06 Jun 2022 4.5 450 0.41 557.95
18 Feb 2022 1.5 150 0.41 656.05
17 Nov 2021 1.5 150 0.41 672
27 Aug 2021 1.5 150 0.41 826.2
22 Feb 2021 1.5 150 0.41 967.95
23 Nov 2020 1.25 125 0.41 810.8
21 Aug 2020 1.25 125 0.41 934.2
17 Feb 2020 1.75 175 0.41 510.5
21 Nov 2019 1.25 125 0.41 433.85
15 Feb 2019 1.25 125 0.41 761.15
20 Nov 2018 1.25 125 0.41 795.95
20 Feb 2018 1 100 0.41 616.1
21 Nov 2017 1.5 150 0.41 789.4
08 Jun 2017 1.25 125 0.41 512.4
24 Nov 2016 1.25 125 0.41 733.9
09 Jun 2016 0.7 70 0.41 785.3
18 Feb 2016 0.7 70 0.41 742.7
19 Nov 2015 0.6 60 0.41 856.65
21 Aug 2015 0.5 50 0.41 744.15
08 Jun 2015 1 100 0.41 1304.2
16 Feb 2015 2 200 0.41 1150.85
13 Aug 2014 1.5 150 0.41 732.3
11 Jun 2014 1.75 175 0.41 638.55
19 Nov 2013 1.25 125 0.41 260.4
30 Jul 2013 0.5 50 0.41 170.4
18 Feb 2013 1 100 0.41 186.4
30 Jul 2012 1 100 0.41 110.4
20 Jul 2011 1 100 0.41 181.35
11 Nov 2010 5 100 0.41 1184.95
13 Sep 2010 2 40 0.41 852.75
05 Feb 2010 3 60 0.41 846.55
16 Dec 2009 1.5 30 0.41 784.85
05 Feb 2009 3 60 0.41 140.2
11 Aug 2008 3.25 65 0.41 327.45
14 Sep 2007 2.5 50 0.41 787.15
08 Sep 2006 1.5 30 0.41 531
20 Sep 2005 0.5 10 0.41 313.3
22 Jul 2004 2.25 45 0.41 359.55
08 Sep 2003 3.5 35 0.41 374.8
19 Sep 2002 3 30 0.41 232.3
0 30 0.41 236.25
12 Sep 2001 0 30 0.41 187.15
10 May 2000 0 50 0.41 462.25
0 50 0.41 485.1
0 15 0.41 80.1

Peers

Other companies within the same industry or sector that are comparable to Aurobindo Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 808.20 -1.14 11.41 624.74 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 57.06 -0.77 237.75 2276.47 14.01 0.88
Vaishali Pharma Ltd 12.12 -5.90 606.00 1173.38 2.31 0.00
Astec Lifesciences Ltd 653.90 -5.55 0.00 2146.51 -239.30 0.00

Company Info

1986 - The company was incorporated on 26th December as a Private Limited company and was converted into a Public Limited company with effect from 30-4-1992. The company is registered with the Registrar of Companies, Andhra Pradesh at Hyderabad. The chief promoters of the Company are Shri P.V. Ramaprasad Reddy and Shri K. Nityananda Reddy. - Aurobindo Pharma Limited is one of the leading manufacturers of life saving anti-biotic bulk drugs in India with excellent track record of profitability and growth. - The Company has developed inhouse technology for manufacture of the bulk drugs as well as formulations. - The Company is one of the largest manufacturers of Ampicillin and Cloxacillin in India. 1992 - Another unit was also set up for the manufacture of CMIC Chloride, a bulk drug intermediate at Pashamylaram, near Hyderabad. Through another Company namely, Chaitanya Organics Pvt. Ltd., which is now being merged with Aurobindo Pharma Limited. - The Company issued Bonus Shares in the ratio of 1:1 in May, in the ratio of 2:1 in June, 1993 and in the ratio of 7:20, in November 1994. - The Company follows the Mercantile System of Accounting and recognises Income and Expenditure on Accrual basis. 1993 - The Company has set up two more units during the year, viz., - i) Bulk drug unit at Bollaram, near Hyderabad. - ii) Formulations unit at Kukatpally, near Hyderabad. - The Company is setting up a Bulk Drug cum Formulation Plant to produce sterile Bulk Drugs like Ampicillin Sodium (Sterile) IP/BP, Cloxacillin Sodium (Sterile) IP/BP, and cephalosporins (Sterile) Bulk Drugs and Formulations in the dosage forms like sterile powder injectables, small volume parenterals, Capsules and Tablets. 1994 - The installed capacity of the Pondicherry Unit of the Company is increased from 204 TPA to 300 TPA during the current year - The Bollaram unit is for the manufacture of anti-biotic bulk drugs, namely Cloxacillin, and Dicloxacillin mainly for exports. - During the Year, the Company has upgraded the plant and increased the installed capacity from 78 TPA to 84 TPA. The Company has set up a separate block in the same premises during the current year, 1994-95 for manufacture of high value drugs namely Astemizole, Domeperidone, Famotidine and Omeprazole, with an installed capacity of 9 TPA. - The Kukatpally unit is for manufacture of pharmaceutical formulations with an installed capacity of 360 lakhs tablets and 480 lakhs capsules per annum. - During the current year the Company has increased the installed capacity of the merged company Chaitanya Organics Pvt. Ltd., from 120 TPA to 144 TPA. Further a new bulk drug intermediate namely DCMIC Chloride is also manufactured in this unit from April. The Company has also expanded the above unit by setting up a separate block for manufacture of Norfloxacillin and Pefloxacillin with an installed capacity of 60 TPA. - The Company proposed to acquire two generators of 250 KVA capacity each as standby arrangement. - The company has entered into domestic formulations market in 5 States and plans to launch in other states shortly. - The Company has agency set-up at Srilanka, Thailand, Russia and Nigeria for marketing its products. It proposes to set up its own marketing offices at Hongkong, Moscow and Nigeria to promote bulk drug sales. - The Company has a connected power load of 500 KVA from A.P.S.E.B. In addition, 3 Generators of 125 KVA capacity each have been installed as a stand by arrangement. - The Company is a member of Patancheru Effluent Treatment Plant Limited and Jeedimetle Effluent Treatment Plant. - All the Assets and Liabilities of M/s. Chaitanya Organics Pvt. Ltd. will be taken over by M/s. Aurobindo Pharma Ltd. with effect from 1st April, on completion of amalgamation formalities. - As per the scheme of amalgamation it is proposed to issue one equity share of M/s. Aurobindo Pharma Ltd. of Rs 10/- each credited as fully paid up for every one equity share of Rs 10/- each fully paid up held in M/s. Chaitanaya Organics Pvt. Ltd. to the Shareholders of M/s. Chaitanya Organics Pvt. Ltd. 1995 - In January, Videocon International and Videocon Appliances sold a tranche of Aurobindo shares to the public at a premium of Rs 180. 1997 - Glaxo (India), the Indian subsidiary of the UK-based multinational, is understood to be negotiating with the Hyderabad-based Aurobindo Pharma for an alliance to meet its global bulk drug requirements. - The annual capacities now stand at 300 million of capsules and 840 tonnes of bulk drugs. - The company proposes to manufacture fourth generation cephalosporins such as 7-ACA, cephalexin, cephatoxime and cephazolin. 1998 - AUROBINDO Pharma Ltd is setting up two wholly-owned subsidiaries in the US and Hong Kong to increase its presence in the international market. - The company is one of the largest bulk manufacturers of semi-synthetic penicillin (SSP) products such as ampicilin and Amoxycillin. It is the world's fourth largest producer of ampicillins and fifth largest producer of amoxycillins. - The company has also launched new formulations like auronim Suspension in the paediatric segment. - The company has obtained the shareholders permission to invest $2,00,000 in the share capital of Aurobindo Pharma (Miami) Inc in USA and $150,000 in the share capital of Aurobindo Pharma (Hong Kong) Pte Ltd. - The company would be launching several new formulations including Roxythromycin, Clarithromycin, Sporfloxocyin, besides Sephradin, a smei-synthetic, in the domestic market. Among sterile products to be launched by the company are Cephazolin, Cehatoxin and Azithromycin. 1999 - The Hyderabad-based Aurobindo Pharma had received in-principle approval from the Board of Industrial and Financial Reconstruction (BIFR) in March to buy the plant. - APL is today the most cost-efficient producer of SSPs in India and a low cost international producer of other value added bulk drugs and drug intermediaries. - Aurobindo currently manufactures three types of drugs including cephalosporin-based formulations, drugs for gastroenterology and pain-related products. - The company proposes to deploy the issue proceeds to part-finance its R&D thrust and the growth of its formulations business. APL plans to meet the further funds requirement for its capital expenditure programme, if any, through internal accruals. - The board of directors has allotted 5,51,000 equity shares of Rs.10 each at a premium of Rs.480 per share by private placement on preferential basis to FIIs, FIs, MFs and bodies corporate etc. - Aurobindo Pharma Ltd, the largest domestic manufacturer of penicillin-based bulk antibiotics, plans to form joint ventures in Brazil and China by the end of financial year 1999-2000 (April-March). 2000 - Aurobindo Pharma Ltd. a major producer of semi-synthetic penicillins in the country, proposes to set up two joint venture companies in the US to manufacture cephalosporins and non-cephalosporins. - Aurobindo Pharma is setting up two joint ventures for formulations in the US, with an investment of $12 million. - As per the scheme of Amalgamation equity shares of Aurobindo Pharma Limited will be exchanged to the shareholders of Sri Chakra Remedies Limited for every 100 equity shares held by them. 2001 - The Company has launched an exclusive anti-viral division -- Immunus -- to educate and to provide preventive drug care for HIV/AIDS patients in the country. - Hyderabad based Aurobindo Pharma has restructured its management responsibilities in view of major growth initiatives to be taken to create a platform for penetrating attractive global markets. P V Ramaprasad Reddy, former managing director, has been appointed executive chairman, while K Nityananda Reddy, former joint managing director and co-promoter, has been appointed managing director, APL informed the Bombay Stock Exchange on July 4. -This new structure is expected to enable the company to concentrate on the "strategies of change" being pursued by it to achieve the goal of becoming a research and development-based international pharmaceutical company, it said, adding that the changes had received board approval. -Aurobindo Pharma Ltd today announced the launch two more drugs-- Efavirenz (Viranz) and Nelfinavir (NELVEX)-- for the treatment of AIDS. 2002 -Three existing Directors, Mr Srinivas Lanka, Mr A J Kamath and Mr A Siva Rama Prasad have stepped down from the directorship, thus making room for appointment of independent external directors. Accordingly, their resignations were accepted. While Mr Srinivas Lanka will be considered for reappointment as non-executive independent Director, Mr A J Kamath will assume the responsibility of group financial advisor. Further, it is planned to retain the services of Mr A Siva Rama Prasad for group operations. -Aurobindo Pharma to allot further equity shares/warrants to promoters. -Srinivas Lanka re-inducted into the Board of Aurobindo Pharma. -Sathyamurthy appointed as Additional Director of Aurobindo Pharma. 2003 -The Board of Directors of Aurobindo Pharma Ltd has approved the appointment of Dr K A Balasubramanian as an additional director on the Board of Directors of the company. Dr Balasubramanian shall be an independent, non-executive director. -Aurobindo informed BSE that Citadel Aurobindo Biotech Ltd, a 50:50 Joint venture company introduced Aztreonam a Monabactam Betalactam antibiotic for the first time in the Indian Pharma Market with a brand name 'TREONAM'. -Aurobindo Tongling (Datong) pharmaceuticals Ltd, China , a JV between APL and Shanxi Tongling Pharmaceuticals co. has set up for manufacture of pharmaceutical products for the local market. -With a view to manufacture Pen G, a raw material essential for the production of semi-synthrtic pencillin, Aurobindo has infused Rs 59cr in a flagship Aurobindo(Datong) Pharma Ltd. -Aurobindo Pharma has launched second joint venture company in US for the purpose of Research and Development. -Allots 950,000 equity shares to promoters/directors by way of conversion of warrants -Aurobindo Pharma has launched second joint venture company in the United States for the purpose of R & D in alliance with Salus Pharmaceuticals. -Aurobindo Pharma has filed around 20 patents in the areas of central nervous system, cardio-vascular, and anti-cholesterol segments. Out of this it is able to obtain 2 of them in United States of America. -UTI sold 3 pc stake from the company -Board approves the issue on a preferential basis, of an aggregate upto 3,100,000 equity shares of Rs.5/- each at a price of Rs.302/- per equity share (including a premium of Rs.297 per equity share), totalling up to Rs.93.62 cr -Company ropes in Merlion India Fund 1, Mauritius, for allotting 31 lakh equity shares on a preferential basis at a price of Rs 302 per share, including a premium of Rs 297 per share, totalling Rs 93.62 crore 2004 - Ms P. Suneela Rani, has sold 6,80,000 equity shares of Rs 5 each of the company, constituting 1.4 per cent of equity of its current paid-up equity of Rs 24.2 crore. These shares were sold in the open market from December 23-31 last year Aurobindo Pharma Ltdhas announced that it has received its first Certificate of Suitability (CoS) approval from the European Directorate for Quality Medicines (EDQM) for its product in the therapeutic segment of gastroenterology. -Aurobindo Pharma Ltd has informed that the members at the EGM of the Company held on December 26, 2003 have unanimously approved the following special resolution : 'Issue of equity shares under preferential allotment guidelines of SEBI'. Further, the Company has also informed that delisting of securities of the company from Ahmedabad Stock Exchange was approved w.e.f. January 15, 2004. -Aurobindo Pharma Ltd has informed that pursuant to the application of the Company, its securities have been removed from the list of the Ahmedabad Stock Exchange (ASE) w.e.f. January 15, 2004. 2005 -USFDA part of Department of health and human science approves UNIT VIII facility as a site to manufacture APIs for the US Market. -Aurobindo AIDS drug receives US FDA clearance -Aurobindo Pharma gets EDQM approval for Flucloxacillin Sodium -Aurobindo Pharma receives approval for Sertraline Hydrochloride Tablets -Aurobindo Pharma receives approval for Cephalexin Capsules by US FDA -Aurobindo's receives final approval of Mirtazapine Orally Disintegrating Tablets 2006 -Aurobindo Pharma receives final approval of Mirtazapine ODT 45mg for US marketAurobindo Pharma receives final approval of Mirtazapine ODT 45mg for US market -Aurobindo Pharma Ltd has announced that the US FDA has granted tentative approval for the Company's Simvastatin Tablets USP 5 mg, 10 mg, 20 mg, 40 mg and 80 mg -Aurobindo receives US FDA approval for Didanosine (Chewable) Tablets -Aurobindo Pharma Ltd has announced that it has received the marketing authorization approval from Medicines Evaluation Board (MEB), NETHERLANDS for Mirtazapine 15, 30 and 45 mg orally disintegrating tablets containing the active ingredient Mirtazapine. -Aurobindo Pharma Ltd has appointed Mr. A.Mohan Rami Reddy as Company Secretary of the Company. -Aurobindo Pharma receives final approval for SIMVASTATIN tablets from USFDA. -Aurobindo arm acquires Dutch firm Pharmacin. 2007 - Aurobindo Pharma Ltd has received one more approval from USFDA for Cefadroxil capsules 500 mg. - Aurobindo Pharma Ltd has announced that on June 13, 2007 the Company unveiled their new Logo and Corporate Identity at a ceremony in Hyderabad. 2008 - Aurobindo Pharma Ltd has announced that the Company has received an approval from the US Food & Drug Administration to market its 300mg Cefdinir Capsules in the US market. The drug falls under the Anti-bacterial segment and is a generic equivalent of Abbott Laboratories, OMNICEF. -Aurobindo Pharma Ltd has appointed Mr. K Raghunathan as an Additional Director of the Company at the Board Meeting held on January 30, 2008. - Aurobindo Pharma Ltd has announced that the Company has been awarded ARV contract worth Rs 70 crores for 3 products which are WHO / USFDA pre-qualified by National Aids Control Organization (NACO). - Aurobindo Pharma Ltd has got final clearance from the US Food and Drug Administration (USFDA) to manufacture and market Didanosine Delayed Release capsules in 125 mg, 200 mg, 250 mg and 400 mg. The drug is indicated for treatment of HIV - 1 infections in adults. It is the generic version of Bristol Myer Squibb's Videx EC delayed-release capsules. 2009 - Aurobindo Pharma Ltd has received Swissmedic approvals for Amlodipine Besylate Tablets and Metformin Hydrochloride Tablets. 2010 - Aurobindo Pharma has received final approval from the United States Food and Drug Administration for its product Ceftazideme injection in different dosages. 2011 "Aurobindo Pharma receives USFDA tentative approval for Famciclovir Tablets" -"Aurobindo Pharma Announces Strategic Divestment of Aurobindo (Datong) Bio Pharma, China" -"Aurobindo Pharma receives USFDA tentative approval for Levofloxacin Tablets". -"Aurobindo Pharma receives USFDA tentative approval for Venlafaxine Extended Release Capsules". -"Aurobindo Pharma receives USFDA tentative approval for Famclclovir Tablets". -"Aurobindo Pharma receives Platinum Certificate of Outstanding Exports Award from Pharmexcil". -Company has splits its Face value of Shares from Rs 5 to Re 1 2012 -"Aurobindo Pharma receives final approvals for Quetiapine Fumarate Tablets". -"Aurobindo Pharma receives final approval for Olanzapine Tablets". -Aurobindo Pharma gets USFDA nod for anti-HIV drugs Lamivudine and Zidovudine -Aurobindo Pharma gets USFDA nod to launch Clopidogrel tablets -"Aurobindo Pharma receives final approval for Metformin Hydrochloride Extended Release Tablets". 2013 -Aurobindo Pharma gets USFDA approval for anti-migraine tablets. - "Aurobindo Pharma receives tentative approval for Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Tablets". -Aurobindo gets final USFDA approval for Cefadroxil oral suspension. -Aurobindo Pharma bags final US FDA approval for Rizatriptan Benzoate ODT. 2014 -"Aurobindo completes the acquisition of Natrol". -"Aurobindo Pharma receives USFDA Approval for Amoxicillin for Oral Suspension". -"Aurobindo completes the acquisition of select Western European Businesses of Actavis". -"Aurobindo Pharma receives USFDA Approval for Divalproex Sodium Extended-Release Tablets". -"Aurobindo Pharma receives USFDA approval for Repaglinide Tablets". 2015 - Aurobindo Pharma has received approval from the USFDA to manufacture and market Valsartan Tablets USP -Aurobindo Pharma gets USFDA nod for Lacosamide Tablets -Aurobindo Pharma receives USFDA Tentative Approval for Lacosamide Tablets -Aurobindo Pharma gets USFDA nod for Lacosamide Tablets -Aurobindo Pharma gets USFDA nod for Sildenafil injection -Aurobindo gets USFDA nod for Atracurium Besylate injections -Aurobindo Pharma receives USFDA Approval for Cefixime for Oral Suspension USP -Aurobindo Pharma receives USFDA approval for Famotidine Tablets --The Company has allotted the Bonus Shares in the Ratio of 1:1. 2016 -Aurobindo Pharma receives USFDA Approval for Norethindrone Acetate Tablets -Aurobindo Pharma receives USFDA Approval for Tranexamic Acid Injection -Aurobindo Pharma receives approval for Voriconazole Tablets -Aurobindo Pharma receives USFDA Approval for Celecoxib Capsules -Aurobindo Pharma bags approval for Acetylcysteine Injection -Aurobindo Pharma receives approval for Naproxen Tablets -Aurobindo Pharma receives USFDA Approval for Pantoprazole Sodium for Injection -Aurobindo receives approval for Amlodipine & Valsartan Tablets -Aurobindo Pharma receives USFDA Approval for Hydromorphone Hydrochloride Tablets 2017 -"Aurobindo Pharma receives USFDA Approval for Levetiracetam in Sodium Chloride Injection". -"Aurobindo's European Subsidiary Signs Binding Agreement to Acquire Generis Farmaceutica SA in Portugal". -"Aurobindo Pharma Forays into Biosimilars Development through an acquisition of Four Products from TL Biopharmaceutical AG". -Aurobindo Pharma receives USFDA Approval for Atomoxetine Capsules. 2018 -Aurobindo Pharma bags approval for Omeprazole tablets. -Aurobindo Pharma bags approval for Ertapenem Injection. -Aurobindo Pharma gets USFDA nod for infection treatment drug. -Aurobindo Pharma signs pact to acquire certain assets from Sandoz. -Aurobindo Pharma arm inks pact with Shandong Luoxin to form JV in China. 2019 -Aurobindo completes acquisition of Apotex & Businesses in five European countries. -" Aurobindo Completes the Acquisition of Marketed Portfolio from Spectrum Pharmaceuticals". -Aurobindo Pharma introduces Cinacalcet Hydrochloride Tablets in US market. 2020 -Aurobindo Pharma ties up with BIRAC to develop COVID-19 vaccine. -CSIR and Aurobindo Pharma collaborate to develop COVID-19 vaccine. -Aurobindo Pharma signs exclusive licensing agreement with COVAXX. 2021 -Aurobindo Pharma receives USFDA approval for Droxidopa Capsules. -Aurobindo Pharma receives NCLT approval for scheme of amalgamation. 2022 -Aurobindo Pharma acquire 51% stake in GLS Pharma Limited. -Aurobindo Pharma arm gets final USFDA nod for Vasopressin injection. - Aurobindo Pharma arm receives USFDA nod for Triamcinolone Acetonide injectable suspension. 2023 -Aurobindo Pharma arm gets USFDA nod for cancer drug. -Aurobindo to launch HIV triple combination product for children living with HIV in low- and middle-income countries under voluntary licence from ViiV Healthcare. 2024 -Aurobindo Pharma has received the first product approval from the US Food and Drug Administration for a generic anaesthesia medication. -Aurobindo Pharma has received its first product approval from the USFDA for Lidocaine Hydrochloride Injection. -Aurobindo Pharma commissions four plants in Andhra Pradesh including Pen-G facility.

1986 - The company was incorporated on 26th December as a Private Limited company and was converted into a Public Limited company with effect from 30-4-1992. The company is registered with the Registrar of Companies, Andhra Pradesh at Hyderabad. The chief promoters of the Company are Shri P.V. Ramaprasad Reddy and Shri K. Nityananda Reddy. - Aurobindo Pharma Limited is one of the leading manufacturers of life saving anti-biotic bulk drugs in India with excellent track record of profitability and growth. - The Company has developed inhouse technology for manufacture of the bulk drugs as well as formulations. - The Company is one of the largest manufacturers of Ampicillin and Cloxacillin in India. 1992 - Another unit was also set up for the manufacture of CMIC Chloride, a bulk drug intermediate at Pashamylaram, near Hyderabad. Through another Company namely, Chaitanya Organics Pvt. Ltd., which is now being merged with Aurobindo Pharma Limited. - The Company issued Bonus Shares in the ratio of 1:1 in May, in the ratio of 2:1 in June, 1993 and in the ratio of 7:20, in November 1994. - The Company follows the Mercantile System of Accounting and recognises Income and Expenditure on Accrual basis. 1993 - The Company has set up two more units during the year, viz., - i) Bulk drug unit at Bollaram, near Hyderabad. - ii) Formulations unit at Kukatpally, near Hyderabad. - The Company is setting up a Bulk Drug cum Formulation Plant to produce sterile Bulk Drugs like Ampicillin Sodium (Sterile) IP/BP, Cloxacillin Sodium (Sterile) IP/BP, and cephalosporins (Sterile) Bulk Drugs and Formulations in the dosage forms like sterile powder injectables, small volume parenterals, Capsules and Tablets. 1994 - The installed capacity of the Pondicherry Unit of the Company is increased from 204 TPA to 300 TPA during the current year - The Bollaram unit is for the manufacture of anti-biotic bulk drugs, namely Cloxacillin, and Dicloxacillin mainly for exports. - During the Year, the Company has upgraded the plant and increased the installed capacity from 78 TPA to 84 TPA. The Company has set up a separate block in the same premises during the current year, 1994-95 for manufacture of high value drugs namely Astemizole, Domeperidone, Famotidine and Omeprazole, with an installed capacity of 9 TPA. - The Kukatpally unit is for manufacture of pharmaceutical formulations with an installed capacity of 360 lakhs tablets and 480 lakhs capsules per annum. - During the current year the Company has increased the installed capacity of the merged company Chaitanya Organics Pvt. Ltd., from 120 TPA to 144 TPA. Further a new bulk drug intermediate namely DCMIC Chloride is also manufactured in this unit from April. The Company has also expanded the above unit by setting up a separate block for manufacture of Norfloxacillin and Pefloxacillin with an installed capacity of 60 TPA. - The Company proposed to acquire two generators of 250 KVA capacity each as standby arrangement. - The company has entered into domestic formulations market in 5 States and plans to launch in other states shortly. - The Company has agency set-up at Srilanka, Thailand, Russia and Nigeria for marketing its products. It proposes to set up its own marketing offices at Hongkong, Moscow and Nigeria to promote bulk drug sales. - The Company has a connected power load of 500 KVA from A.P.S.E.B. In addition, 3 Generators of 125 KVA capacity each have been installed as a stand by arrangement. - The Company is a member of Patancheru Effluent Treatment Plant Limited and Jeedimetle Effluent Treatment Plant. - All the Assets and Liabilities of M/s. Chaitanya Organics Pvt. Ltd. will be taken over by M/s. Aurobindo Pharma Ltd. with effect from 1st April, on completion of amalgamation formalities. - As per the scheme of amalgamation it is proposed to issue one equity share of M/s. Aurobindo Pharma Ltd. of Rs 10/- each credited as fully paid up for every one equity share of Rs 10/- each fully paid up held in M/s. Chaitanaya Organics Pvt. Ltd. to the Shareholders of M/s. Chaitanya Organics Pvt. Ltd. 1995 - In January, Videocon International and Videocon Appliances sold a tranche of Aurobindo shares to the public at a premium of Rs 180. 1997 - Glaxo (India), the Indian subsidiary of the UK-based multinational, is understood to be negotiating with the Hyderabad-based Aurobindo Pharma for an alliance to meet its global bulk drug requirements. - The annual capacities now stand at 300 million of capsules and 840 tonnes of bulk drugs. - The company proposes to manufacture fourth generation cephalosporins such as 7-ACA, cephalexin, cephatoxime and cephazolin. 1998 - AUROBINDO Pharma Ltd is setting up two wholly-owned subsidiaries in the US and Hong Kong to increase its presence in the international market. - The company is one of the largest bulk manufacturers of semi-synthetic penicillin (SSP) products such as ampicilin and Amoxycillin. It is the world's fourth largest producer of ampicillins and fifth largest producer of amoxycillins. - The company has also launched new formulations like auronim Suspension in the paediatric segment. - The company has obtained the shareholders permission to invest $2,00,000 in the share capital of Aurobindo Pharma (Miami) Inc in USA and $150,000 in the share capital of Aurobindo Pharma (Hong Kong) Pte Ltd. - The company would be launching several new formulations including Roxythromycin, Clarithromycin, Sporfloxocyin, besides Sephradin, a smei-synthetic, in the domestic market. Among sterile products to be launched by the company are Cephazolin, Cehatoxin and Azithromycin. 1999 - The Hyderabad-based Aurobindo Pharma had received in-principle approval from the Board of Industrial and Financial Reconstruction (BIFR) in March to buy the plant. - APL is today the most cost-efficient producer of SSPs in India and a low cost international producer of other value added bulk drugs and drug intermediaries. - Aurobindo currently manufactures three types of drugs including cephalosporin-based formulations, drugs for gastroenterology and pain-related products. - The company proposes to deploy the issue proceeds to part-finance its R&D thrust and the growth of its formulations business. APL plans to meet the further funds requirement for its capital expenditure programme, if any, through internal accruals. - The board of directors has allotted 5,51,000 equity shares of Rs.10 each at a premium of Rs.480 per share by private placement on preferential basis to FIIs, FIs, MFs and bodies corporate etc. - Aurobindo Pharma Ltd, the largest domestic manufacturer of penicillin-based bulk antibiotics, plans to form joint ventures in Brazil and China by the end of financial year 1999-2000 (April-March). 2000 - Aurobindo Pharma Ltd. a major producer of semi-synthetic penicillins in the country, proposes to set up two joint venture companies in the US to manufacture cephalosporins and non-cephalosporins. - Aurobindo Pharma is setting up two joint ventures for formulations in the US, with an investment of $12 million. - As per the scheme of Amalgamation equity shares of Aurobindo Pharma Limited will be exchanged to the shareholders of Sri Chakra Remedies Limited for every 100 equity shares held by them. 2001 - The Company has launched an exclusive anti-viral division -- Immunus -- to educate and to provide preventive drug care for HIV/AIDS patients in the country. - Hyderabad based Aurobindo Pharma has restructured its management responsibilities in view of major growth initiatives to be taken to create a platform for penetrating attractive global markets. P V Ramaprasad Reddy, former managing director, has been appointed executive chairman, while K Nityananda Reddy, former joint managing director and co-promoter, has been appointed managing director, APL informed the Bombay Stock Exchange on July 4. -This new structure is expected to enable the company to concentrate on the "strategies of change" being pursued by it to achieve the goal of becoming a research and development-based international pharmaceutical company, it said, adding that the changes had received board approval. -Aurobindo Pharma Ltd today announced the launch two more drugs-- Efavirenz (Viranz) and Nelfinavir (NELVEX)-- for the treatment of AIDS. 2002 -Three existing Directors, Mr Srinivas Lanka, Mr A J Kamath and Mr A Siva Rama Prasad have stepped down from the directorship, thus making room for appointment of independent external directors. Accordingly, their resignations were accepted. While Mr Srinivas Lanka will be considered for reappointment as non-executive independent Director, Mr A J Kamath will assume the responsibility of group financial advisor. Further, it is planned to retain the services of Mr A Siva Rama Prasad for group operations. -Aurobindo Pharma to allot further equity shares/warrants to promoters. -Srinivas Lanka re-inducted into the Board of Aurobindo Pharma. -Sathyamurthy appointed as Additional Director of Aurobindo Pharma. 2003 -The Board of Directors of Aurobindo Pharma Ltd has approved the appointment of Dr K A Balasubramanian as an additional director on the Board of Directors of the company. Dr Balasubramanian shall be an independent, non-executive director. -Aurobindo informed BSE that Citadel Aurobindo Biotech Ltd, a 50:50 Joint venture company introduced Aztreonam a Monabactam Betalactam antibiotic for the first time in the Indian Pharma Market with a brand name 'TREONAM'. -Aurobindo Tongling (Datong) pharmaceuticals Ltd, China , a JV between APL and Shanxi Tongling Pharmaceuticals co. has set up for manufacture of pharmaceutical products for the local market. -With a view to manufacture Pen G, a raw material essential for the production of semi-synthrtic pencillin, Aurobindo has infused Rs 59cr in a flagship Aurobindo(Datong) Pharma Ltd. -Aurobindo Pharma has launched second joint venture company in US for the purpose of Research and Development. -Allots 950,000 equity shares to promoters/directors by way of conversion of warrants -Aurobindo Pharma has launched second joint venture company in the United States for the purpose of R & D in alliance with Salus Pharmaceuticals. -Aurobindo Pharma has filed around 20 patents in the areas of central nervous system, cardio-vascular, and anti-cholesterol segments. Out of this it is able to obtain 2 of them in United States of America. -UTI sold 3 pc stake from the company -Board approves the issue on a preferential basis, of an aggregate upto 3,100,000 equity shares of Rs.5/- each at a price of Rs.302/- per equity share (including a premium of Rs.297 per equity share), totalling up to Rs.93.62 cr -Company ropes in Merlion India Fund 1, Mauritius, for allotting 31 lakh equity shares on a preferential basis at a price of Rs 302 per share, including a premium of Rs 297 per share, totalling Rs 93.62 crore 2004 - Ms P. Suneela Rani, has sold 6,80,000 equity shares of Rs 5 each of the company, constituting 1.4 per cent of equity of its current paid-up equity of Rs 24.2 crore. These shares were sold in the open market from December 23-31 last year Aurobindo Pharma Ltdhas announced that it has received its first Certificate of Suitability (CoS) approval from the European Directorate for Quality Medicines (EDQM) for its product in the therapeutic segment of gastroenterology. -Aurobindo Pharma Ltd has informed that the members at the EGM of the Company held on December 26, 2003 have unanimously approved the following special resolution : 'Issue of equity shares under preferential allotment guidelines of SEBI'. Further, the Company has also informed that delisting of securities of the company from Ahmedabad Stock Exchange was approved w.e.f. January 15, 2004. -Aurobindo Pharma Ltd has informed that pursuant to the application of the Company, its securities have been removed from the list of the Ahmedabad Stock Exchange (ASE) w.e.f. January 15, 2004. 2005 -USFDA part of Department of health and human science approves UNIT VIII facility as a site to manufacture APIs for the US Market. -Aurobindo AIDS drug receives US FDA clearance -Aurobindo Pharma gets EDQM approval for Flucloxacillin Sodium -Aurobindo Pharma receives approval for Sertraline Hydrochloride Tablets -Aurobindo Pharma receives approval for Cephalexin Capsules by US FDA -Aurobindo's receives final approval of Mirtazapine Orally Disintegrating Tablets 2006 -Aurobindo Pharma receives final approval of Mirtazapine ODT 45mg for US marketAurobindo Pharma receives final approval of Mirtazapine ODT 45mg for US market -Aurobindo Pharma Ltd has announced that the US FDA has granted tentative approval for the Company's Simvastatin Tablets USP 5 mg, 10 mg, 20 mg, 40 mg and 80 mg -Aurobindo receives US FDA approval for Didanosine (Chewable) Tablets -Aurobindo Pharma Ltd has announced that it has received the marketing authorization approval from Medicines Evaluation Board (MEB), NETHERLANDS for Mirtazapine 15, 30 and 45 mg orally disintegrating tablets containing the active ingredient Mirtazapine. -Aurobindo Pharma Ltd has appointed Mr. A.Mohan Rami Reddy as Company Secretary of the Company. -Aurobindo Pharma receives final approval for SIMVASTATIN tablets from USFDA. -Aurobindo arm acquires Dutch firm Pharmacin. 2007 - Aurobindo Pharma Ltd has received one more approval from USFDA for Cefadroxil capsules 500 mg. - Aurobindo Pharma Ltd has announced that on June 13, 2007 the Company unveiled their new Logo and Corporate Identity at a ceremony in Hyderabad. 2008 - Aurobindo Pharma Ltd has announced that the Company has received an approval from the US Food & Drug Administration to market its 300mg Cefdinir Capsules in the US market. The drug falls under the Anti-bacterial segment and is a generic equivalent of Abbott Laboratories, OMNICEF. -Aurobindo Pharma Ltd has appointed Mr. K Raghunathan as an Additional Director of the Company at the Board Meeting held on January 30, 2008. - Aurobindo Pharma Ltd has announced that the Company has been awarded ARV contract worth Rs 70 crores for 3 products which are WHO / USFDA pre-qualified by National Aids Control Organization (NACO). - Aurobindo Pharma Ltd has got final clearance from the US Food and Drug Administration (USFDA) to manufacture and market Didanosine Delayed Release capsules in 125 mg, 200 mg, 250 mg and 400 mg. The drug is indicated for treatment of HIV - 1 infections in adults. It is the generic version of Bristol Myer Squibb's Videx EC delayed-release capsules. 2009 - Aurobindo Pharma Ltd has received Swissmedic approvals for Amlodipine Besylate Tablets and Metformin Hydrochloride Tablets. 2010 - Aurobindo Pharma has received final approval from the United States Food and Drug Administration for its product Ceftazideme injection in different dosages. 2011 "Aurobindo Pharma receives USFDA tentative approval for Famciclovir Tablets" -"Aurobindo Pharma Announces Strategic Divestment of Aurobindo (Datong) Bio Pharma, China" -"Aurobindo Pharma receives USFDA tentative approval for Levofloxacin Tablets". -"Aurobindo Pharma receives USFDA tentative approval for Venlafaxine Extended Release Capsules". -"Aurobindo Pharma receives USFDA tentative approval for Famclclovir Tablets". -"Aurobindo Pharma receives Platinum Certificate of Outstanding Exports Award from Pharmexcil". -Company has splits its Face value of Shares from Rs 5 to Re 1 2012 -"Aurobindo Pharma receives final approvals for Quetiapine Fumarate Tablets". -"Aurobindo Pharma receives final approval for Olanzapine Tablets". -Aurobindo Pharma gets USFDA nod for anti-HIV drugs Lamivudine and Zidovudine -Aurobindo Pharma gets USFDA nod to launch Clopidogrel tablets -"Aurobindo Pharma receives final approval for Metformin Hydrochloride Extended Release Tablets". 2013 -Aurobindo Pharma gets USFDA approval for anti-migraine tablets. - "Aurobindo Pharma receives tentative approval for Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Tablets". -Aurobindo gets final USFDA approval for Cefadroxil oral suspension. -Aurobindo Pharma bags final US FDA approval for Rizatriptan Benzoate ODT. 2014 -"Aurobindo completes the acquisition of Natrol". -"Aurobindo Pharma receives USFDA Approval for Amoxicillin for Oral Suspension". -"Aurobindo completes the acquisition of select Western European Businesses of Actavis". -"Aurobindo Pharma receives USFDA Approval for Divalproex Sodium Extended-Release Tablets". -"Aurobindo Pharma receives USFDA approval for Repaglinide Tablets". 2015 - Aurobindo Pharma has received approval from the USFDA to manufacture and market Valsartan Tablets USP -Aurobindo Pharma gets USFDA nod for Lacosamide Tablets -Aurobindo Pharma receives USFDA Tentative Approval for Lacosamide Tablets -Aurobindo Pharma gets USFDA nod for Lacosamide Tablets -Aurobindo Pharma gets USFDA nod for Sildenafil injection -Aurobindo gets USFDA nod for Atracurium Besylate injections -Aurobindo Pharma receives USFDA Approval for Cefixime for Oral Suspension USP -Aurobindo Pharma receives USFDA approval for Famotidine Tablets --The Company has allotted the Bonus Shares in the Ratio of 1:1. 2016 -Aurobindo Pharma receives USFDA Approval for Norethindrone Acetate Tablets -Aurobindo Pharma receives USFDA Approval for Tranexamic Acid Injection -Aurobindo Pharma receives approval for Voriconazole Tablets -Aurobindo Pharma receives USFDA Approval for Celecoxib Capsules -Aurobindo Pharma bags approval for Acetylcysteine Injection -Aurobindo Pharma receives approval for Naproxen Tablets -Aurobindo Pharma receives USFDA Approval for Pantoprazole Sodium for Injection -Aurobindo receives approval for Amlodipine & Valsartan Tablets -Aurobindo Pharma receives USFDA Approval for Hydromorphone Hydrochloride Tablets 2017 -"Aurobindo Pharma receives USFDA Approval for Levetiracetam in Sodium Chloride Injection". -"Aurobindo's European Subsidiary Signs Binding Agreement to Acquire Generis Farmaceutica SA in Portugal". -"Aurobindo Pharma Forays into Biosimilars Development through an acquisition of Four Products from TL Biopharmaceutical AG". -Aurobindo Pharma receives USFDA Approval for Atomoxetine Capsules. 2018 -Aurobindo Pharma bags approval for Omeprazole tablets. -Aurobindo Pharma bags approval for Ertapenem Injection. -Aurobindo Pharma gets USFDA nod for infection treatment drug. -Aurobindo Pharma signs pact to acquire certain assets from Sandoz. -Aurobindo Pharma arm inks pact with Shandong Luoxin to form JV in China. 2019 -Aurobindo completes acquisition of Apotex & Businesses in five European countries. -" Aurobindo Completes the Acquisition of Marketed Portfolio from Spectrum Pharmaceuticals". -Aurobindo Pharma introduces Cinacalcet Hydrochloride Tablets in US market. 2020 -Aurobindo Pharma ties up with BIRAC to develop COVID-19 vaccine. -CSIR and Aurobindo Pharma collaborate to develop COVID-19 vaccine. -Aurobindo Pharma signs exclusive licensing agreement with COVAXX. 2021 -Aurobindo Pharma receives USFDA approval for Droxidopa Capsules. -Aurobindo Pharma receives NCLT approval for scheme of amalgamation. 2022 -Aurobindo Pharma acquire 51% stake in GLS Pharma Limited. -Aurobindo Pharma arm gets final USFDA nod for Vasopressin injection. - Aurobindo Pharma arm receives USFDA nod for Triamcinolone Acetonide injectable suspension. 2023 -Aurobindo Pharma arm gets USFDA nod for cancer drug. -Aurobindo to launch HIV triple combination product for children living with HIV in low- and middle-income countries under voluntary licence from ViiV Healthcare. 2024 -Aurobindo Pharma has received the first product approval from the US Food and Drug Administration for a generic anaesthesia medication. -Aurobindo Pharma has received its first product approval from the USFDA for Lidocaine Hydrochloride Injection. -Aurobindo Pharma commissions four plants in Andhra Pradesh including Pen-G facility.

Read More

Parent Organisation

Aurobindo Pharma Ltd.

Founded

26/12/1986

Managing Director

Mr.K Nithyananda Reddy

NSE Symbol

AUROPHARMAEQ

FAQ

The current price of Aurobindo Pharma Ltd is ₹ 1094.75.

The 52-week high for Aurobindo Pharma Ltd is ₹ 1117.10 and the 52-week low is ₹ 1090.00.

The market capitalization of Aurobindo Pharma Ltd is currently ₹ 63583.26. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Aurobindo Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Aurobindo Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Aurobindo Pharma Ltd shares.

The CEO of Aurobindo Pharma Ltd is Mr.K Nithyananda Reddy, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT